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Dendritic cells (DC) are the most potent professional antigen-presenting cells 
(APC) with exquisite capacity to interact with T cells to initiate strong primary 
cellular immune response.  The antigen-presenting capability of DC makes them 
the excellent vehicles for the delivery of therapeutic cancer vaccines.  DC 
generated in vitro have been proven a potent inducer of immunity, however, in 
vivo exploitation of DC to optimize the immunogenicity of vaccines has not been 
fully explored.  This project investigates peptide- and DNA-based vaccine 
approaches which involve delivering signal that expand and recruit DC at the 
antigen administration or production site (in situ). 
 
In peptide-based strategy, a 30 mer human muc-1 peptide was designed and the 
immunogenicity of the peptide was tested by loading onto in vitro cultured bone 
marrow-derived DC (BM-DC).  Mice immunized with muc-1 pulsed BM-DC, 
but not muc-1 peptide, generated potent muc-1 specific cellular response. We 
then hypothesized that the expansion of DC in situ will enhance APC activity and 
would subsequently increase the host’s cellular immune responses to exogenous 
peptides.  Flt-3L is a haematopoietic factor which expands and matures DC in 
both mice and humans.  We demonstrated that administration of muc-1 peptide 
following DC expansion with Flt-3L gene in vivo generates potent muc-1-specific 
cellular response and anti-tumor response.  This suggests that in situ loading and 
activating of DC is a feasible and convenient approach for immunotherapy of 
human malignancies as it requires no DC manipulation ex-vivo.  
 ix
In order to enable a more efficient approach, a DNA construct, termed pNGVL3-
hFLex-muc-1, was generated encoding the extracellular domain of human Flt-3L 
ligated to the muc-1 epitope, so as to express a secretory fusion protein which 
exhibits dual functionality, cognizant of its respective components.  It is 
postulated that the transfected cells will express and secrete the muc-1 fusion 
protein, thereby allowing uptake by DC, which will then process and present the 
antigen to lymphocytes. Hydrodynamic-based intravenous delivery of pNGVL3-
hFLex-muc-1 DNA vaccine induces cytotoxic T lymphocytes (CTL) response but 
fails to elicit protective anti-tumor response.  In contrast, intramuscular 
immunization, a conventional DNA vaccine delivery route, with pNGVL3-
hFLex-muc-1 DNA vaccine generated a potent anti-tumor response. The 
pNGVL3-hFLex-muc-1 DNA vaccine recruited massive CD11c+/CD8α- DC to 
the muscular immunization site, suggesting a mechanism through which 
immunity was generated against the muc-1 epitope expressed by pNGVL3-
hFLex-muc-1 DNA vaccine. 
 
In conclusion, we devised two strategies of inducing DC to prime muc-1 specific 
anti-tumor response in vivo.  It is suggested that the availability of DC at the 
antigen site (in situ) is a critical factor to enhance the immunogenicity of both 
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1.1   Dendritic cells (DC) in tumor immunotherapy 
Despite rapid advances in cancer therapy, the current tumor treatment usually 
does not promise a permanent cure for cancer patients.  Tumor recurrence 
remains a major setback for cancer therapy, therefore, novel and effective 
treatment is urgently needed.  The identification of tumor-associated antigen 
(TAA) has provided the opportunity for generating tumor specific immunity to 
eradicate tumor.  The most exciting aspect of stimulating an endogenous 
immune response is its potential in initiating long-term immunological 
memory. This may provide a permanent cure for the cancer patients whereby a 
long-lived anti-tumor immune response can be elicited. 
 
For the past decades, many efforts have been attempted to understand the 
induction and regulation of tumor immunity.  The basic premise of 
immunotherapy for cancer is to stimulate the immune system in some way to 
treat and even prevent cancer in the form of vaccination.  A crucial step for 
mounting an effective anti-tumor response is the capturing, processing and 
presentation of TAA to cognate T cells by professional antigen-presenting cells 
(APC).  Dendritic cells (DC) are professional antigen presenting cells (APC) with 
exquisite capability to activate naive T cells and hence induction of primary 
immune response.  DC, loaded with antigen ex vivo, have been shown to induce 
potent anti-tumor response [1-2].  The generation of clinically relevant immune 
responses by antigen-loaded DC could be demonstrated for certain types of 
human malignancies [3-4].   Antigen-specific T cell immunity can be detected in 
cancer patients following immunization with various DC regimes [5].  These 
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findings have provided a compelling rational for using DC as an attractive target 
for therapeutic manipulation of the immune system.  It is evident that DC have 
several features that could be modulated using appropriate designed vaccines to 
generate stronger T cell immunity.  Although DC are present in most tissues at 
very low frequency, relatively large number of DC can be obtained through the in 
vitro propagation of their progenitors [6-7].  However, the wide application of 
DC for clinical immunotherapy is still difficult and far from ideal.  While 
extensive animal studies have been conducted using DC, optimal parameters in 
humans remain to be established.  There are several aspects of DC biology that 
are of critical in determining the quantity and quality of the immune response to 
the TAA, since DC are heterogeneous in terms of origin, morphology, 
phenotypes and functions.  Therefore, a comprehensive research on these aspects 
could provide useful information in obtaining optimal immune response to TAA.  
 
1.2  Parameters of DC-based vaccines 
1.2.1   Subsets of DC 
1.2.1.1  Subsets of murine DC 
Multiple murine DC subsets have been identified in lymphoid (spleen, thymus 
and lymph node) and non-lymphoid (liver, heart, mucosa and skin) organs based 
on the phenotypic analysis.  However, there is inherent difficulty in studying 
these DC subsets which is present in such a low number within the multiple 
tissue sites.  In mice, CD11c, an integrin αx chain, is expressed on all defined DC 
subsets [8].  Meanwhile, lymphoid tissues contain two distinct DC sub-
populations based on the differential expression of CD8α marker, which was first 
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described in the thymus [9].  CD8α exists as a CD8αβ heterodimer on T cells, in 
contrast, DC express CD8α homodimer on cell surfaces [10].  However, the 
functional role of the CD8α marker on DC remains to be unveiled.  In spleen and 
lymph nodes (LN), the CD8α- DC can be further sub-divided into CD4+ and 
CD4- DC subsets [11].  In LN, there are another two DC populations being 
identified, the interstitial tissue DC (CD4-CD8-CD11b+) and Langerhans DC 
(CD4-CD8loCD205+CD11b+) [12].  Mature Langerhans cells are restricted mainly 
to the skin-draining lymph nodes while mature interstitial tissues DC are common 
to all lymph nodes.  Plasmacytoid DC represent a distinct class of DC recently 
identified in bone marrow, thymus, spleen and LN [13].  They express B220 (B-
cell marker) and Gr-1(granulocyte antigen) but low levels of CD11c and MHC-
class II.  In addition, they display characteristics that differ from other DC subsets 
by having typical morphology of large, round cells with a diffuse nucleus and 
rare dendrites. 
 
Based on the CD8α phenotype, it was initially postulated that CD8α-DC are of 
myeloid origin and CD8α+ DC are of lymphoid origin [14].  However, the 
reliability of CD8α as a DC lineage marker is now questionable.  Lineage study 
on mice deficient for the Ikaros (Ikaros DN -/-), a transcription factor required for 
the development of defined haematopoietic lineages, does not allow definite 
conclusions to be drawn on the origin of DC.  In the Ikaros DN-/- mice, 
differentiation of myeloid cells is normal but there is a severe defect in the 
development of lymphoid cells and dendritic cells [14].  This suggests that 
myeloid progenitors alone are not sufficient to DC development.  In agreement 
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with the above investigation, other studies showed that common lymphoid 
progenitors (CLP) or common myeloid progenitors (CMP) could differentiate 
into both CD8α+ and CD8α- DC [15-16], demonstrating that CD8α+ and CD8α-
DC could be derived from two distinct differentiation pathways rather than from 
different lineages.  Therefore, it has been proposed that the differential expression 
of surface markers on different DC populations may reflect the different 
maturation or activation stages rather than separate sub-lineages. 
 
Although multiple DC subtypes have been identified and characterized, definition 
of distinct functional capacity of each of these different subsets lags well behind 
phenotypic identification.  Early studies showed that CD8α+ DC prime TH1 
response by producing IL-12 p70 heterodimer whereas CD8α- DC direct TH2 
response [17].  However, it has been shown recently that both DC subsets 
produce IL-12 and are efficient in stimulating T cells proliferation in vitro [18].  
One distinct property of DC is their ability to cross-present antigen, in this 
regards, exogenous antigen gains access to MHC class I presentation pathway 
instead of conventional MHC class II pathway.  Both CD8α- and CD8α+ DC 
subsets possess the ability to cross-present soluble antigen T cells in vivo [19].  
Moreover, the efficiency of cross-presentation can be further enhanced when 
soluble antigens are complexed with IgG [20].  The enhanced efficiency of 
antigen uptake is related to the expression of Fcγ receptors (FcγR) on DC [21].  
DC have increased expression of FcγRII and FcγRIII but lower expression of 
FcγRI [22].  In the absence of FcγRI and III, CD8α- DC lost the ability to cross-
present immune complexes in the context of MHC class I molecules.  However, 
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the absence of the two FcγRs did not abrogate the ability of CD8α+ DC in the 
cross-presentation [22].  Upon activation by antigen capturing, DC in the 
peripheral tissues will start to migrate to the lymphoid organs such as spleen and 
LN by expressing various chemokines or receptors on their cell surfaces.  CD8α- 
DC exhibit the superior ability in trafficking in vivo.  When donor CD8α- or 
CD8α+ DC were given to recipient mouse subcutaneously, only CD8α- DC could 
be found later in the draining LN [23].  The inferior ability of CD8α+DC to 
migrate in vivo might correlate with CCR7 expression.  The lower expression of 
CCR7 on CD8α+DC could impair the ability to traffic from peripheral tissues to 
secondary lymphoid organs.  These studies underscore the importance of 
migratory properties of DC in initiating and regulating specific immune response  
 
1.2.1.2  Subsets of human DC  
There are relatively more studies on mouse DC subsets as compared to human 
DC freshly isolated from tissue.  In 1992, Inaba et al [24] identified proliferating 
cells in mouse blood that differentiated into DC after 7d culture in GM-CSF.  
Several studies on blood DC or their progenitors are soon followed due to the fact 
that blood is the ready and the most convenient source of human DC.  Blood DC 
are heterogeneous in lineage or differentiation pathway.  Three populations of 
human DC in the peripheral blood have been identified using a panel of 
antibodies (Abs): CD1a+/CD11c+, CD1a-/CD11c+ and CD1a-/CD11c- DC 
subsets [25].  CD1a+/CD11c+ and CD1a-/CD11c+ DC show more potent APC 
activity and monocyte-like morphology, suggesting myeloid-origin (M-DC).  
CD1a+/CD11c+ DC have the capacity to become Langerhans cell (LC) in the 
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presence of GM-CSF+IL-4+TNF-β, suggesting direct precursor of LC.  The 
human Langerhans-cell DC is recognized as a separate DC subtype with an 
immature phenotype of myeloid origin as a result of their unique Birbeck 
granules (BGs), langerin expression and heterogeneous maturation process.  In 
contrast, CD1a-/CD11c- DC show lymphoplasmacytoid morphology, dependent 
on IL-3 but not GM-CSF, suggesting the lymphoid origin of these DC [26].  This 
DC subset is later termed plasmacytoid DC (pDC) with the capability to secrete 
high level of IFN-α/β upon viral infection [27].  They can be found in blood and 
many lymphoid tissues, entering LN by E-selectin-dependent transfer across high 
endothelial venules [28].  It has been suggested that at least some of these 
plasmacytoid cells are of lymphoid origin where they express many lymphoid 
markers (CD4, CD62L and CD123), lacking surface myeloid markers [25].  
Myeloid and plasmacytoid DC differ widely in their capacity to migrate to 
chemotatic stimuli.  The distinct migration behavior of DC subsets is 
accompanied by a different chemokine and their receptors.  Plasmacytoid DC, as 
compared to myeloid DC, express higher level of chemokine receptors like 
CCR5, CCR7 and CXCR5 [29].   
 
Murine homologues of human blood DC have recently been described in which 
two populations of precursor DC in mouse blood was identified and 
characterized.  The first population being the mouse blood cells with the surface 
phenotype CD11cloCD11b-CD45RAhi closely resembles human plasmacytoid 
cells by morphology and function [30].  On stimulation with oligonucleotides 
containing CpG motifs, these cells make large amounts of type 1 interferons and 
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rapidly develop into DC that bear CD8α marker, though they may be distinct 
from the CD8α+ DC in the unstimulated mouse.  A second population of cells 
with the surface phenotype, CD11c+CD11b+CD45RA-, closely resembles the 
immediate precursors of myeloid DC, rapidly transforming into CD8α- DC upon 
tumor necrosis factor-alpha (TNF-α) stimulation [30].  However, human DC are 
lacking of CD8α expression as compared to murine DC, therefore direct 
comparison between human and murine DC is difficult.  
 
However, most of the insights into DC subsets and their developmental origin 
derive mostly from the in vitro generation of DC instead of freshly isolated DC.  
To generate human DC, the earliest precursor used is a CD34+ fraction isolated 
from bone marrow or umbilical cord blood which containing haematopoietic 
stem cells and progenitor cells [31].  CD34+ haematopoietic cells isolated from 
cord blood when cultured with GM-CSF and TNF-α leads to two types of 
intermediate precursors and two apparently separate pathways of DC 
development.  These two intermediate DC precursors are CD1a+ and CD14+ 
precursors [32].  The CD1a+ DC precursors will develop into Langerhans 
(epidermal) DC whereas the CD14+ DC precursors will differentiate into DC 
resembling interstitial (dermal) DC, lacking Birbeck granule and the langerhan 
cell antigen.  However, CD14+ DC precursors can differentiate into macrophage-
like cells in the presence of M-CSF [33].  In addition to human cord blood and 
marrow, adult peripheral blood is the most accessible source for DC 
immunotherapy.  Although CD34+ cells are rare in adult peripheral blood, in the 
presence of IL-4, GM-CSF and TNF-α, a large aggregates of DC can be 
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generated (3-8 millions DCs/40ml blood ) [32].  The other source of generating 
human DC is using blood monocytes (CD14+, CD1a-), supplemented with GM-
CSF and IL-4.  Their final maturation stage (CD86 and MHC-class II ) is initiated 
by cytokines such as TNF-α or microbial product such as LPS [34].  These 
mature DC have potent allo-stimulatory activity. 
 
Therefore, the increasing understanding of various DC subsets may allow the 
targeting of TAA to specific DC subsets for controlled immune response and 
hence enhancing the vaccine efficacy. 
 
1.2.2   Maturation stages of DC 
The study of the antigen processing and presentation pathways has greatly 
contributed to our understanding of immune response. Regulating the antigen 
processing and presentation pathway is one of the possible ways to design or 
improve the efficacy of tumor vaccine.  Immature DC are efficient in capturing 
foreign particles/antigens (Ag), microbial and viral products through endocytosis 
including pinocytosis, phagocytosis and receptor-mediated endocytosis [35-37].  
In endocytosis, the cell engulfs some of its extracellular fluid (ECF) including 
material dissolved or suspended in it.  A portion of the plasma membrane is then 
invaginated and pinched off forming a membrane-bounded vesicle called an 
endosome.  Phagocytosis (“cell-eating”) results in the ingestion of particulate 
matter (i.e. bacteria) from the ECF and forming a phagosome and then delivered 
into lysosomes through membrane fusion.  Once inside the lysosome, the 
contents of the phagosome are destroyed by the degradative enzymes of the 
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lysosome.  Pinocytosis (“cell-drinking”) is the ingestion of dissolved materials 
into a pinocytic vesicle.  The liquid contents of the vesicle are then slowly 
transferred to the cytosol.  Receptor-mediated endocytosis allows the uptake of 
macromolecules through specialised regions of the plasma membrane termed 
coated pits.  This process is initiated by recognition of a wide range of molecules 
via receptors on the DC surfaces.  For examples, heat shock proteins bearing 
antigenic peptides from tumor or necrotic cells are recognised through CD91 [38] 
whereas scavenger receptors such as CD36 recognises apoptotic cells [39].  
Furthermore, members of the C-type lectin family i.e. macrophage-mannose 
receptor and DEC205 bind a wide variety of pathogen antigens [40-41].  
Immature DC also express certain immunoglobulin Fcγ and complement 
receptors.  Unlike mature DC, immature DC express relatively low level of 
MHC-class II and co-stimulatory molecules [42].  Most of the MHC-class II 
molecules are sequestered intracellularly in the late endocytic compartments [43].  
A fraction of the cell surface’s MHC-class II molecules are likely internalized 
into lysosome via endocytosis [43]. 
 
Antigens taken up by immature DC are not efficiently utilized for the formation 
of MHC-class II complex in lysosomes, but are retained for use several days later 
in peripheral tissues [44].  This implies that immature DC can take up antigen 
efficiently but do not present it efficiently to T cells.  Immature DC had been 
shown to induce immune tolerance instead of immune stimulation [45-46].  
Therefore, maturation stages of DC are a critical parameter to consider in 
immunization for cancer patients.  Most DC in the peripheral tissues are of the 
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immature type.  Pro-inflammatory cytokines and microbial products such as LPS 
can induce the maturation of immature DC [47].  In contrast to immature DC, 
mature DC have a reduced capacity for antigen uptake but increased efficiency in 
antigen presentation to naive T cells [48].  The transition from immature DC to 
mature phenotypes is accompanied by a series of cellular changes including 
cytokines production and redistribution of MHC-class II from intracellular 
compartments to the plasma membrane [49].  In addition, there is an increased 
expression of co-stimulatory molecules (CD80 and CD86) and T cell adhesion 
molecules (CD48 and CD58) [42].  Furthermore, migratory and homing 
properties are also altered by remodeling of DC chemokine receptors and ligands 
profile [50]. 
 
1.2.3   Antigen capturing, processing and presentation of DC 
One of the unique features of DC is the ability to present exogenous Ag to class I 
pathway [51-53].  This process is termed cross-presentation or indirect 
presentation.  Indirect presentation of class I-restricted antigens by professional 
APC is an important pathway in priming CTL responses in vivo.  In the classical 
antigen presentation pathway, exogenous proteins are generally presented on 
MHC-class II whereas endogenous synthesized proteins are destined for MHC-
class I presentation.  However, there are increasing number of reports 
demonstrate that this division is not absolute and significant cross over can occur 
in professional APC especially for DC system.  This has been supported by the 
morphological evidence where protein taken up by micropinocytosis can gain 
access to the cytosol and then into class l pathway [54].  Bone marrow-derived 
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macrophages have also been shown to present exogenous soluble Ag uptaken by 
macropinocytosis to class l pathway [55].  Based on these findings, a unique 
pathway for presentation on class l of exogenous protein might exist for DC 
through regulation of their multiple specialized endosomal system.   
 
Recently, it was found that DC express the known member of the CD1 family of 
antigen-presenting molecules.  CD1a is typically found on epidermal Langerhans 
cells in skin, while CD1b and CD1c are expressed on dermal DC [56].  The CD1 
molecules are involved in the presentation of microbial glycolipids i.e. CD1d on 
monocyte derived-DC can present the alpha-galactosyceramide-containing drug 
[57].  In addition, CD1d represent a non-MHC-restricted recognition of NKT 
cells [57].  NKT cells orchestrate the production of large amounts of cytokines 
from several cell types and have the capacity to act as adjuvants for T cell -
mediated immunity.  The versatile of DC in antigen presentation definitely 









Destruction of tumor cells
 
Figure 1.1  Cell-mediated immunity against cancer.  There are four types of 
lymphocytes to kill cancer cells.  CD8+ CTL recognize tumor peptides presented 
on MHC-class I and the killing of target cells is mediated by granzyme-
dependent mechanism [58].  CD4+ CTL recognize tumor peptides presented on 
MHC-class II and the target cells are destroyed via fasL-dependent mechanism 
[59-61].  NK and NKT cells recognize target cells lacking MHC-class I 
molecules as well as glycolipids [62-63]. 
 
1.2.4   Antigen-loading onto DC   
The use of DC in cancer immunotherapy has been greatly facilitated by the 
development of methods to isolate and propagate DC in vitro.  To induce an 
effective tumor-specific CTL response which will lead to tumor eradication, TAA 
must be loaded onto MHC class I molecules.  There are various methods to 
deliver TAA to DC in vitro, however, studies of in vivo loading of TAA are still 
lacking.  For defined antigenic tumor epitopes, one of the most convenient ways 
is loading 9-11mer peptides directly onto DC [64].  Melanoma patients 
vaccinated with melanoma-peptide-pulsed DC generated antigen specific immune 
response [4].  However, recently longer peptide like polypeptide (180 a.a) had 
been shown to be presented to MHC-class I when loaded onto DC [65].  It is 
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postulated that the longer peptide is processed to shorter peptide which will be 
loaded onto MHC-class I molecules.  The disadvantages of DC pulsed with TAA 
synthetic peptides approach including; the uncertainty regarding the longevity of 
antigen presentation, the restriction by the patient's haplotype and the relatively 
lower number of known MHC class I-related epitopes.  In addition, the soluble 
peptides or proteins are captured by DC less efficiently than particulate antigens.  
The conjugation of TAA to anti-Fcγ receptor (FcγR) antibody has increased the 
efficiency of DC in capturing soluble peptides or proteins [66].  The entry of 
TAA-conjugated to FcγR antibody is facilitated by FcγR receptor-mediated 
endocytosis. This approach is particularly practical when soluble peptides or 
proteins are to be loaded onto DC in vivo efficiently.  Furthermore, knock-out 
mice impaired in the inhibitory Fcγ receptor could greatly enhance DC-based 
vaccination [67].   
 
The utilisation of viral vectors genetically modified to express TAA for the ex 
vivo transduction of DC is another attractive alternative to achieve a MHC I- and 
MHC II-restricted presentation of tumor antigens.  Replication-defective 
oncoretroviruses including adeno/retro/vaccinia/lenti carrying the TAA are able 
to efficiently transduce DC [68-70].  DC expressing the lentiviral vector-encoded 
Flu peptide was shown at least as efficient as DC pulsed with the same peptide in 
stimulating specific CTL [70].  The efficacy of the lentivirus-transduced DC was 
further demonstrated by their ability to directly activate freshly harvested 
peripheral blood Flu-specific CTL in the absence of CD4 + helper T-cell and 
exogenous cytokines [70].   
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For undefined TAA epitopes, DC-pulsed with tumor lysate [71] or transfected 
with RNAs [72], that represent the whole antigenic repertoire of tumor, can be 
employed.  However, other than TAA, the tumor lysates and RNAs contain many 
autoantigens which might lead to autoimmune diseases.  DC transfected with 
mRNAs encoding a chimeric hTERT/lysosome-associated membrane protein 
(LAMP-1) induced specific CD8+ and CD4+ T cell response in vitro [73].  Cells 
undergoing programmed cell death (apoptosis) are rapidly cleared in vivo by 
phagocytes without inducing inflammation.  Recently, it has been discovered that 
apoptotic bodies may represent a way to deliver information to the immune 
system. DC possess the capability to engulf and process apoptotic bodies.  
MAGE-3 specific CTL response was generated where DC acquire MAGE-3 
antigen from apoptotic tumor cells [74].  The capture of apoptotic bodies is likely 
through the cross-presentation mechanism. 
 
An attempt to employ tumor cell-DC cell hybrid as vaccine has sucessfully 
induced regression of renal cell carcinoma in patients [75].  However, the 
generation and maintainance of tumor cell-DC cell hybrid is laborious and 
difficult to standardize. 
 
1.2.5   Migratory and homing properties of DC 
The ability of DC to migrate has allowed them to exert continuous surveillance to 
foreign antigens or pathogens.  Immature DC traffic from blood to tissues to 
capture antigens and then leave the tissues and move to the draining lymphoid 
organs to prime naive T cells in a mature state.  An important attribute of DC at 
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various stages of their maturation is their mobility.  The migratory capacity and 
residence in a given tissue of DC is regulated by chemotactic factors released by 
the target tissue and modulation of surface adhesion molecules [76].  Human 
immature DC derived from CD34+ progenitor cells respond vigorously to MIP-
3α, RANTES, and MIP-1α [76].  Upon maturation, DC lose their responsiveness 
to these chemokines to become sensitive to a single chemokine, macrophages 
inflammatory protein 3-β (MIP-3β) [76].  As MIP-3β can attract mature DC and 
lymphocytes, they are likely to play a key role in helping antigen-loaded DC to 
meet specific T cells.   In addition, DC have differential expression of chemokine 
receptors such as CCR1 (receptor for RANTES), CCR2 (receptor shared by 
MCP-1 and MCP-3), CCR3 (receptor for eotaxin), CCR5 (receptor for MIP-1α 
and β, and RANTES), CCR6 (receptor for MIP-3α), and CCR7 (receptor for 
MIP-3β).  CCR1, CCR5, and CCR6 are expressed on immature DC and are 
down-regulated during maturation [77-78]. Conversely, CCR7 is lacking on 
immature DC but is induced upon activation [79]. 
 
The understanding of DC migration will definitely provide new avenues for 
therapeutic intervention.  For example, DC can be targeted to specific vaccination 
sites by exploiting various chemokines or their receptors.  
 
1.2.6   DC and the development of cancer vaccines 
There is a large body of literature collections where in vitro generated DC are 
active in eliciting protective/therapeutic immune response in murine model 
[1,80] and to a lesser extent in human studies.  Several DC-based studies have 
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been carried out in melanoma patients.  Vaccination of melanoma patients with 
melanoma peptides (MAGE-3, gp100 and MART 1) pulsed DC induced 
antigen-specific T cell immunity [4,81].  However, DC-vaccination with in 
vitro generated DC is not feasible for large-scale immunization.  Therefore, the 
ability to expand DC in situ circumvents many practical problems currently 
associated with the culturing of DC from their BM progenitors in vitro.  The in 
vitro generation of BM-DC needs to employ many expensive cytokines.  For 
example, GM-CSF is commonly employed for the culturing DC in vitro.  
Moreover, the culturing of DC in vitro might face additional problems such as 
contamination and the possibly changes in the physiological properties of DC.  
Thus, there is a need to develop strategies that can provide a robust 
protective/therapeutic immunization response.  An effective cancer vaccine 
should compose of TAA and activation molecules/adjuvants.  DC have long 
been described as natural adjuvant for immune response.  Therefore, employing 
DC in cancer vaccine development is a rational and practical approach.  Upon 
understanding the various biological properties of DC, vaccine efficacy could 
be improved, perhaps, by altering DC functions in several ways: 1) by in vivo 
increasing of DC number by stimulating DC replication or survival signal by 
Flt-3 ligand (FL) [82]  2) by recruitment of DC in situ by Flt-3L or 
chemokines/chemokine receptors  3) by enhancing vaccine capturing and 
processing by DC  4) by promoting DC maturation  and 5) by targeting antigen 
to specific DC subset.  
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In our study, we hypothesize that the expansion of DC in situ will enhance 
APC and would subsequently increase the ability of the immunized host’s 
cellular immune responses to exogenous antigen (MUC-1).  In vivo DC 
expansion can be achieved with human Flt-3 ligand. 
 
1.3   Flt-3 ligand (FL) and cancer immunotherapy 
1.3.1   FL and DC  
FL has a remarkable effect on DC expansion in vivo.  Although GM-CSF is 
efficient in stimulating DC expansion in vitro, however, when employed in vivo, 
GM-CSF alone did not induce significant DC augmentation in vivo [83].  In 
murine model, daily subcutaneous injection of human recombinant FL (hFL) in 
mice for 9–10 days causes a significant increase in the numbers of DC in both 
lymphoid ( spleen, LN and thymus) as well as non-lymphoid tissues (blood, intra-
peritoneal cavity and liver) [82].  Administration of hFL expands both CD8α+ 
and CD8α- DC subsets in murine spleen [82].  Interestingly, the levels of DC in 
various organs return to normal levels following cessation of FL treatment [82].  
This suggests the existence of a regulatory mechanism to maintain a stable pool 
of DC population.  In addition, hFL can augment NK cell numbers although to a 
lesser extent as compared to DC [84].  The administration of hFL does not appear 
to have overt toxicity in murine model.  hFL has gained much attention since 
Lynch and colleagues [85] demonstrated the potent anti-tumor activity exerted by 
hFL in a SCID mouse model in 1997.  Massive infiltration of DC was found 
within the tumor site as revealed by immunohistochemistry staining, suggesting a 
role of DC in generating the anti-tumor response.  Soon following the above 
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report, several studies further demonstrated the tumor suppression capability of 
hFL in an immuno-competent murine cancer model [86].  The anti-tumor effect 
of hFL could be attributed to the specific tumor-associated CTL immunity or 
non-specific NK cells activity. 
 
Murine FL, like hFL counterpart, can augment DC efficiently when administered 
in vivo.  However, some of the phenotypic characteristics of the murine FL-
expanded DC (mFL-DC) are different from human FL-expanded DC (hFL-DC).  
mFL increases DC in vivo and the increase was heavily biased to CD8+ DC [87].  
In addition, mFL-DC express high level of B220 but hFL-DC have minimal 
expression of B220 [88].  A B220+ DC sub-population was recently described 
that exerts tolerogenic effects in their steady state [88].  hFL injections have been 
reported to increase the splenic NK cells but the number of splenic NK cells did 
not change appreciably by over expression of mFL.  Interestingly, in some of the 
in vivo model, mFL-DC induced tolerogenic effects on T cells.  Adoptive transfer 
of antigen-pulsed mFL-DC to naive mice indeed caused faster rates of tumor 
growth [88].  
 
1.3.2   Structure and expression of FL 
The differential effect of mFL and hFL on DC subsets expansion may be related 
to the structural differences and expression pattern of FL and their receptor (Flt-
3).  FL gene encodes a type I transmembrane protein.  The mouse and human 
proteins contain 231 and 235 amino acids, respectively [89-90].  The FL protein 
composed of a signal peptide, extracellular domain, transmembrane domain and 
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cytoplasmic tail.  The first 27 (mouse) or 26 (human) amino acids constitute a 
signal peptide that is absent from the mature protein, followed by a 161 (mouse) 
or 156 (human) amino acid extracellular domain, a 22 (mouse) or 23 (human) 
amino acid transmembrane domain, and a 21 (mouse) or 30 (human) amino acid 
cytoplasmic tail [89-90].  The greatest homology between mouse and human FL 
lying within the extracellular domain which has 73% identity in a.a. sequence 
whereas the cytoplasmic domain has 52% homology.  Furthermore, the mouse 
and human FL proteins each contain two potential sites for N-linked 
glycosylation [89]. 
 
Both mouse and human FL exist in many isoforms [89-95].  Human FL occurs 
mainly as the full-length transmembrane isoform, which can be proteolytically 
cleaved into the spacer and tether region to generate a second soluble isoform 
which is devoid of the transmembrane domain.  Another rare isoform of FL has 
an alternatively spliced exon 6 that creates a premature stop codon, resulting in a 
slightly different soluble form of the protein.  Unlike human FL, the most 
abundant isoform of mouse FL is a 220-amino-acid, membrane associated 
protein.  This membrane-associated isoform results from the failure to splice out 
an intron.  A soluble variant of mouse FL, similar to the soluble variant of human 
FL with an alternatively spliced exon 6, has also been identified.  All human and 
mouse isoforms of FL are biologically active, however the relative activity and 
biological relevance of the different isoforms remains to be clarified.  
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FL is expressed by most tissues, including haematopoietic organs (spleen, 
thymus, peripheral blood and bone marrow), prostate, ovary, kidney, lung, colon, 
small intestine, testis, heart and placenta [89].  However, the brain is one of the 
few tissues without demonstrable expression of FL [89].  
 
1.3.3   FL in normal cells and tissues 
FL-mediated responses are highly-dependent on the cell type and other growth 
factors that are acting on the cell.  FL affects the growth of pluripotent 
haematopoietic stem cell and progenitor cells and a number of lineages in the 
lymphoid and myeloid pathways.  However, FL alone has little proliferative 
effects on defined subpopulations of stem and progenitor cells.  However, when 
added with other growth factors such as IL-3, G-CSF, CSF, GM-CSF and kit 
ligand, the proliferative response is greatly enhanced [96].  FL alone is unable to 
support the colony growth of ThyloSca-1+Linlo stem cells isolated from mouse 
BM but synergies with IL-3 or IL-6 [97].  Studies showed that human fetal bone 
marrow stimulated with FL in combination with IL-7 promoted stromal-cell-
independent growth of pro-B cells and the differentiation of pro-B cells to pre-B 
cells [98].  FL synergized with GM-CSF and IL-3 and with/without c-kit ligand 
to promote the growth and colony formation of CD34+ cells isolated from human 
BM and cord blood [99].  On the other hand, TGF-β and TNF-α can inhibit the 
proliferative activity of FL [100-102].  In addition to in vitro condition, the in 
vivo haematopoietic effects of FL have also been investigated.  Administration of 
FL in mice induces a significant expression of haematopoietic progenitor cells 
[97]. 
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1.3.4  Effects of FL on T, B, and NK cell development 
Freedman and colleagues [103] studied the role of FL on T cell development by 
in vitro culturing CD34+ human BM progenitors on primary irradiated fetal-
thymic stromal cell.  In the presence of IL-12, T cell receptors positive cells were 
produced and the number of these cells was further enhanced if FL was added to 
the culture [103].  Other reports showed that FL in the combination of IL-3 or IL-
6 or IL-7 preferentially stimulate the T cells development from the most primitive 
thymic progenitor cells [104].  Flt-3 deficient mice showed reduced number of T 
cell progenitors but normal levels of T cells, owing to the fact that FL acts at a 
very early stage of T cell development [105].  Experiments showed that human 
fetal bone marrow found that stimulation with FL in combination with IL-7 
promoted stromal-cell-independent growth of pro-B cells and the differentiation 
of pro-B cells to pre-B cells [98].  Flt-3 deficient mice have a reduced numbers of 
both pro- and pre-B cells progenitors, suggesting a critical role of FL in early B 
cell development [105].   NK is a distinct lymphocyte population that mediates 
cytotoxic killing in an MHC-independent manner.  In human, cytokines like IL-2, 
IL-15 and c-kit ligand influence the differentiation of NK cells from human 
CD34+ haematopoietic progenitors [106].  
 
1.3.5   Structure and expression of Flt-3 
Flt-3 belongs to the receptor tyrosine kinase (RTK) subclass III family member. 
Other family members include macrophage colony stimulating factor (MCF) 
receptor, steel factor receptor (kit) and platelet-derived growth factor (PDGF) 
receptor.  Flt-3 composed of five immnoglobulin like extracellular domains, 
 22
transmembrane domain, juxtamembrane domain, and two intracellular kinase 
domains linked by a kinase-insert domain [107].  Flt-3 plays an important role in 
the proliferation, differentiation and survival of normal haematopoietic cells.  In 
human, two isoforms of Flt-3 have been described: a 158-160-kDa membrane-
bound that is glycosylated at the extracellular domain and an unglycosylated 130-
143-kDa non-membrane-bound protein [108]. 
 
In contrast to the widely expression of FL in many tissues, Flt-3 has a more 
restricted tissue expression.  In mouse, Flt-3 expression has been detected in the 
spleen, thymus and peripheral blood.  B cells, T cells and peritoneal macrophages 
have been reported to express the message for the Flt-3 [109].  In mouse BM, 
expression is restricted to blast cells, monocytes and a small subsets of 
lymphocytes [110].  Among the lymphocyte population, Flt-3 expression is 
restricted to pre-and pro-B cells and the most immature form of mouse 
thymocytes [111].  Flt-3 expression is not evident on mature B or T cell subsets 
[111].  In human, the Flt-3 expression has been reported in BM, liver, spleen, 
thymus and the placenta [112].  In the BM, Flt-3 is detected on CD34+ cells, but 
not on CD34- cells [113-114].  Most of the human CD34+ BM and cord blood 
cells (80%) express Flt-3.  These cells also express CD33, a myeloid marker, 
suggesting that the receptor is expressed on subsets of myeloid progenitor cells 
[115].  Flt-3 also express on haematopoietic stem cells but not on mature lympho-
haematopoetic stem cells.  However, monocytes and granulocytes are weakly 
positive for Flt-3 [112]. 
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The targeted disruption of Flt-3 gene, surprisingly, leads to normally developed, 
healthy and fertile adult animals and normal mature haematopoietic populations. 
There is a deficiency in B cell progenitors, NK and DC population.  The Flt-3 
deficient mice have a lifespan of 306 weeks with a dramatic reduction in the 
number of myeloid and lymphoid B and T cells [105].  In addition, reduced 
cellularity of thymus, BM and progenitor populations were detected.  
Transplantation of a mixture of haematopoietic progenitor cells with either non-
functioning or wild-type Flt-3 led to reconstitution of the BM cells that mainly 
expressed wild-type Flt-3 [105, 116].  This suggests that Flt-3 confer growth-
advantage.  Knock-out mice of both Flt-3 and Kit developed lethal 
haematopoietic deficiencies.  Therefore, Flt-3 has an important but not absolutely 
necessary function in haematopoiesis.   
 
1.4   Tumor associated antigens (TAA) 
1.4.1   Overview 
The identification of tumor associated antigens (TAA) has provided an 
alternative for tumor therapy intervention.  TAA can be classified into several 
groups: 1) antigens unique to a cancer type  2) antigens common to all cancer 
type  3) antigens originated from differentiation markers.  Currently, anticancer 
vaccine against several TAA are extensively under study such as gp100, MAGE, 
MART-1, HER-2/neu, CEA and MUC-1 [117-119]. 
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1.5   MUC-1 
1.5.1  Discovery of MUC-1 
MUC-1 is one of the TAA which are under extensive studies and belong to mucin 
family members.  Mucins are heterogeneous family of high molecular weight 
(>250 kDa) gycoproteins which are expressed on epithelial tissues like 
respiratory tract, gastrointestinal tract, salivary gland, breast, ovary, trachea gall 
bladder and stomach.  MUC-1 was previously named polymorphic epithelial 
mucin (PEM) due to the extensive polymorphism attributable to different 
numbers of the tandem repeat, ranging from 20 to 125 [120-121].  PEM is of 
particular interest at the time as monoclonal antibodies HMFG-1 and HMFG-2 
was found recognizing both normal and malignant human epithelial cells [122].  
Hence, this leads to the cloning of mucin partial cDNA from human mammalian 
epithelium which first demonstrated the concept of tandem repeat.  At that time, 
it was surprising that the same core protein was cloned from breast and pancreatic 
cancer cells. This is because the antibodies recognized the mature form of the 
protein from breast and pancreatic tissues did not cross-react.   In view of the 
clinical importance of mucins, it is of great interest to study the full structure of 
its core protein, hence this leads to the elucidation of full-length of PEM cDNA 
which was later termed MUC-1.  Subsequently, several genes encoding for 
different mucin polypeptides have been identified and some of these genes are 
expressed in a tissue specific fashion.  To date, there are at least 18 human mucin 
genes identified: MUC-1, MUC-2, MUC-3A, MUC-3B, MUC-4, MUC-5AC, 
MUC-5B, MUC-6, MUC-7, MUC-8, MUC-9, MUC-11, MUC-12, MUC-13, 
MUC-15, MUC-16, MUC-17 and MUC-18.  (Table 1.1)[123-138].   
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Table 1.1  Members identified in mucin family 
 
Mucin Form Chromosome Tissue 
MUC-1 membrane 1q21 Breast, ovary, pancreas, GI, GU 
and respiratory tract  
MUC-2 Secreted 11p15.5 GI 
MUC-3* membrane 7q22 GI 
MUC-4* membrane 3q29 Respiratory tract/Bronchus  
MUC-5AC Secreted 11p15.5 Trachea, gall bladder 
MUC-5B Secreted 11p15.5 Trachea, gall bladder 
MUC-6 Secreted 11p15.6 Stomach 
MUC-7 Secreted 4q13 Salivary gland 
MUC-8 Secreted 12q24.3 Respiratory tissues 
MUC-9 Secreted 1p13 fallopian tube 
MUC-11 membrane 7q22 colon 
MUC-12 membrane 7q22 colon 
MUC-13* membrane 3q13.3 intestine, trachea, kidney, appendix, 
stomach 
MUC-15 membrane 11p14.3 spleen, thymus, prostate, testis, 
ovary, intestine,colon 
MUC-16* membrane 19p13.3 ovary 
MUC-17 membrane 7q22 intestine 
GI: Gastrointestinal tract; GU: genitourinary tract   
* alternate spliced variants exist which can lead to secreted form of mucin  
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Figure 1.2  MUC-1 exists in both membrane-bound and secreted form 
 
MUC-1 is expressed by most glandular and ductal epithelial cells and some 
hematopoietic cell lineages.  The MUC-1 gene contains seven exons which 
generate protein diversity by a series of alternative splicing events that occur in 
the regions located upstream and downstream to a central tandem repeat array.  
The major expressed form of MUC-1 uses all seven exons and is a type 1 
transmembrane protein with a large extracellular tandem repeat domain.  Other 
alternative splice variants of MUC-1 includes a form lacking the mucin–like 
repeat domain, designated MUC-1/Y [139] and a secreted form lacking the 
hydrophobic region required for anchorage to the cell membrane, designated 
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MUC-1/SEC [140].  The tandem repeat domain is highly O-glycosylated and 
alterations in glycosylation have been shown in epithelial cancer cells [141].  
MUC-1 consists of varying number of (20-125) a conserved tandem repeat 
coding for a 20-amino acid.  Each tandem repeat contains five potential 
glycosylated sites. The cytoplasmic domain contains seven tyrosine residues and 
a proposed clathrin-mediated endocytic signal sequence. The extracellular 
domain of the membrane tethered sub-unit shows sequence similarity to the 
ligand binding domain of members of the cytokine receptor superfamily. 
 
1.5.3   O-glycosylation in mammalian cells 
O-glycosylation of serine and threonine is initiated by the action of a family 
Golgi resident ppGalNAc transferases (T1-T13) [142-143].  Many of which 
possess unique ranges of peptide substrate preferences.  O-glycan elongation 
continues in the Golgi by the action of a series of specific transferases that 
sequentially add sugars to the growing oligosaccharide side chain.  The overall 
diversity of the O-glycan depends on many factors including the expression 
levels of transferases, the concentration of sugar nucleotide substrates, the sub-
Golgi localization of transferases and the competition of transferase for acceptor.  
Chains are generally extended by the addition of polylactosamine side chains and 
terminated by the addition of sialic acid, fucose or galactose.  Peptide substrates 
specificity of GalNAc can be readily accounted for the site specific glycosylation 
patterns presently observed for longer O-linked glycans.  However, not much is 
known about the site-specific glycosylation.  Study suggests that neighboring 
peptide core R-GalNAc residues are primarily responsible for the effect. These 
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findings further support the notion that the formation of the Core 1 structure, an 
important initial step in O-glycan biosynthesis, may be regulated to a large extent 
by neighboring residue glycosylation.  The relationship between glycosylation 
pattern and cancer remains to be unraveled.  Interestingly, It was found that 
sialylated core 1 but not core 2 based O-linked glycans accelerated tumor growth 
in MUC-1-transgenic mice [144] 
 
1.5.4  Mouse homologue of human MUC-1 
In 1991, the mouse homologue of the human MUC-1 was cloned [145].  The 
mouse muc-1 shows conservation in potential O-glycosylation sites, 
transmembrane and cytoplasmic domain.  The tandem repeat region encoding 16 
repeats of 20-21 amino acids where 40% composed of serine, threonine and 
proline residues, a typical site for O-glycosylation. .However, unlike human 
MUC-1, mouse muc-1 does not exhibit variable number tandem repeat 
polymorphism.  Moreover, the tandem repeat domain between human and mouse 
MUC-1 only showed 34% homology in protein sequences. 
 
Repeat homology: Human: GSTAPPAHGVTSAPDTRPAP 
   Mouse: DSTSSPVMSGTSSPATSAPX   
 
On the other hand, protein sequence homology increases to 87% in the 
transmembrane and cytoplasmic domain.  There is 74% homology in promoter 
DNA sequences. 
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      Signal peptide                                          tandem repeat                                       transmembrane    cytoplasmic  
34% 87%  87% 
Figure 1.3  Protein homology between human and mouse MUC-1 
 
1.5.5   Cellular functions of MUC-1 
Originally, it was assumed that MUC-1 had a purely protective role via its mucin 
repeat domain, which forms an elongated rigid structure extending well above 
other molecules in the glycocalyx.  However, subsequent studies have 
demonstrated that MUC-1 might play a role in cell-cell adhesion, signaling and 
interaction with cytoskeleton network.  The evolutionary conservation of the 
MUC-1 cytoplasmic tail (MUC-1-CT) sequence suggests it plays an integral role 
in the function of MUC-1.  Zrihan-Licht et al. [146] first demonstrated that the 
CT of MUC-1 and MUC-1/Y could be tyrosine phosphorylated and the CT 
contained a putative binding motif for the signalling molecule Grb2, a ras 
pathway adaptor protein.  Subsequent studies showed an association between 
Grb2 and SOS-1 and with β-catenin in breast cancer cells [147]. However, the 
only demonstration of altered MUC-1 phosphorylation is an increase in serine 
phosphorylation in the MUC-1/Y isoform after binding of the MUC-1/SEC [148].  
The involvement of MUC-1 in intracellular signaling is further supported by co-
precipitation of MUC-1 with other phosphorylated proteins [148]. 
Phosphorylation has been demonstrated occuring at times of cell migration or 
contact.  However, further research is required to reveal the ligands and/or 
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conditions that trigger MUC-1 signalling and to determine the downstream 
consequences. 
 
Analysis of primary human adenocarcinomas revealed that MUC-1/β-catenin 
interaction occurs in both primary and metastatic tumors, but is dramatically 
increased in metastatic lesions [149-150].  Addition of MUC-1 cytoplasmic 
domain peptides to the invasive breast cancer cell lines increases their invasive 
capability and these peptides co-localize with both β-catenin and the focal 
adhesion protein vinculin, primary at sites of membrane invasion into a collagen 
matrix [151].  This supports that MUC-1 might promote the invasive 
tumorigenesis in breast cancer through the modulation of β-catenin localization 
and subsequent cytoskeletal dynamics.  β-catenin is a component of the adherens 
junctions of mammalian epithelial cells, binds directly to the cytoplasmic domain 
of the transmembrane E-cadherin protein that functions in Ca2+-dependent cell-
cell interaction.  Then α-catenin binds to β-catenin and thereby links the complex 
to the actin cytoskeleton.  Cadherin-catenin complex is essential for adherens 
junction function.  It was found that signaling of β-catenin and the MUC-1 
protein is regulated by the c-src tyrosine kinase [152].  This indirectly showed 
that interaction of MUC-1 with c-src is regulated by c-src-dependent signals.   
 
1.5.6   MUC-1 and cancer 
Mucin is known to be highly expressed and underglycosylated in carcinomas that 
show invasive growth and poor prognosis.  MUC-1 has been implicated in the 
progression and behaviour of several cancers.  This has been well documented in 
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breast and ovarian cancer where MUC-1 is over-expressed. RT-PCR, 
immunohistochemistry and in-situ hybridization analysis showed that not only 
the MUC-1 is overexpressed in carcinoma, but the glycosylation pattern is altered 
[153]. Several circulating mucinous markers, including CA 15.3, MCA, CA 459 
and CASA, are secreted products of the polymorphic MUC-1 gene, and are used 
as diagnostic tools in patients with breast cancer [154].  In clinical practice, the 
measurement of the levels of these markers in the blood can give important 
information on the tumor response to treatment and its biological behavior during 
disease monitoring.  Recent data showed that other carcinomas also showed 
aberrant expression of MUC-1.  Prostate cancer and metastatic prostate cancer all 
express high levels of under-glycosylated MUC-1 [155].  It had been shown that 
MUC-1, mapped to the chromosomal band 1q21, is rearranged or amplified in 
15% of B-cell lymphomas and that rearrangement led to over-expression of 
MUC-1 mucin in a case of diffuse large B-cell lymphoma (DLBCL) [156].  The 
band 1q21 is among the most common sites affected by chromosomal 
translocations in lymphoid, myeloid, epithelial and sarcomatous lesions [157].  In 
addition, MUC-1 activation by chromosomal translocation, rearrangement and 
amplification, were also identified in Non-Hodgkin lymphoma (NHL), 
suggesting a role in tumorigenesis [158].   
 
However, the relationship between mucin and cancer remains unclear.  Therefore, 
the changes in the expression and glycosylation pattern have stimulated 
investigations into how these changes contribute to the cancer progression. To 
address the function of MUC-1 in tumor progression and metastasis, MUC-1 
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transgenic mouse that over expresses MUC-1 has been created using homologous 
recombination [159].  MUC-1 overexpression results in spontaneous 
development of unifocal mammary gland carcinomas.  It had been reported that 
the tumor-associated MUC-1 is a ligand for intercellular adhesion molecule 1 
(ICAM-1) [160]. Antibodies to ICAM-1 and to MUC-1 inhibited adhesion of 
human and transfected mouse MUC-1-positive cell lines to human umbilical vein 
endothelial cell monolayers and immobilized recombinant human ICAM-1-
immunoglobulin fusion protein.  Hence, the interaction between MUC-1 and 
ICAM-1 may be critical to the process of blood borne metastases in breast 
cancer. 
 
1.5.7   MUC-1 and immunotherapy 
Finn and colleagues [161] first showed that CTL isolated from tumor-draining 
LN of breast cancer patients specifically recognize breast and pancreatic tumor 
cells in a MHC-unrestricted manner.  However, this recognition is tumor-specific 
because other tumors of epithelial origin or the natural killer target K562 are 
unresponsive to the CTL.  Moreover, antibody SM3, directed against a 
determinant on the mucin protein core (PDTRP epitope) preferentially expressed 
on malignant cells, is able to significantly inhibit lysis of tumor cells by the CTL, 
while other antibodies binding to different core epitopes are not.  Normal breast 
epithelial lines, which also express mucin but not the SM3 epitope, are not lysed 
by these tumor-reactive CTL [161]. This demonstrates that the mucin core 
epitope expressed on tumor cells, but not on normal epithelial cells, can be 
recognized by tumor-reactive CTL.  In addition, the ovarian CTL isolated from 
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ovarian tumors mediated the lysis of tumor targets after in vitro stimulation [162].  
The CTL lysed mucin core-peptide transfected cells, but not targets transfected 
with an expression construct containing a mucin frame-shift mutant cDNA as 
control, demonstrating the specificity in killing.  Moreover, targets pulsed with 
short synthetic peptides composed of amino acids 1-14 of the MUC-1 core 
peptide repeat were also lysed by the same CTL.  Again, this lysis was inhibited 
by the mAb SM3 that recognize an epitope on the mucin core peptide.  The 
MHC-unrestricted recognition has been proposed due to the repetitive nature of 
the mucin which allows cross-linking of the T-cell receptor on mucin-specific T-
cells [162]. Subsequent peptide mapping studies identified certain MHC-
restricted epitopes [163].  In the mouse model, the MUC-1 recognition is MHC-
restricted.  Anti-muc-1 antibody against the tandem repeat region can also be 
detected in human sera from breast, pancreatic and colon cancer patients [164-
165].  Collectively, these findings form the basis for an effective vaccine to 
augment the PDTRP epitope specific immune response.  
 
Several clinical trials on human subjects have been carried out for the past few 
years.  A 105 amino acid (a.a.) synthetic MUC-1 peptide containing 5 repeated 
immunodominant epitopes had been used to immunize patients [166].  To further 
enhance the muc-1 specific immune response, the patients were vaccinated with 
the synthetic mucin peptide admixed with BCG.  All together, there were 63 
patients were vaccinated with 100μg of 105 a.a mucin peptide mixed with BCG. 
The examination of 55 biopsies from 37 patients showed intense T-cell 
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infiltration whereas 7 patients had lesser T cell infiltration.  Seven out of 22 
patients tested had a 2-to-4-fold increase in mucin-specific CTLp frequency.  
 
In the mouse model, mannan-conjugated MUC-1 had been demonstrated to 
induce strong CTL response accompanied by anti-tumor response [167].  This 
encouraging result has prompted a human clinical trial on the mannan-conjugated 
MUC-1.  There are 25 patients with advanced metastatic carcinoma of breast, 
colon, stomach or rectum were vaccinated with mannan conjugated MUC-1 
[168].  13 out of 25 patients produced high IgG1 anti-muc-1 antibodies.  These 
antibodies reacted with STAPPAHG and PAPGSTAP epitope.  T cell 
proliferation was detected in 4 out of 15 patients whereas 2 out of 10 patients 
demonstrated CTL responses.  Unlike in mice, mannan-conjugated MUC-1 
induced a humoral response rather than a cellular response in human trials.  
 
On the other hand, MHC-class I restricted CTL were generated in patients 
immunized with a synthetic MUC-1 peptide (16 a.a.) (GVTSAPDTRPAPGSTA) 
(5 μg) conjugated to KLH admixed with an adjuvant [169].  All together, there 
were 16 patients were being tested. Three patients developed an anti-muc-1 IgG 
response which was weak in magnitude.  In vitro stimulation of patients’ T cells 
with synthetic muc-1 peptide showed class-I restricted killing of MUC-1-
expressing tumor cell lines in 7 of these patients.  Recently, a phase I clinical trial 
using a recombinant vaccinia virus encoding MUC-1 and IL-2 was conducted in 
breast cancer patients [170].  Cancer patients were injected intramuscularly with 
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the recombinant vaccinia virus.  These cancer patients showed augmentation of 
Th1 response. 
  
Taken together, the underglycosylation of MUC-1 in many cancers has made 
MUC-1 an attractive target for cancer vaccine.   Therefore, more potent MUC-1 
immunotherapy need to be devised for effective tumor eradication.   
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1.6  Project overview 
The project is aimed at devising DC-based cancer vaccines for muc-1-expressing 
tumor. Our strategy is focused on in vivo manipulation of DC to enhance vaccine 
potency.  Our approach is based on the assumption that the expansion of DC in 
situ will enhance antigen presentation and would subsequently increase the 
ability of the immunized host’s cellular immune responses to exogenous antigens.   
Peptide- and DNA-based approaches that involve delivering signal that expand 
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Figure 1.4  Immunogenicity of muc-1-pulsed bone marrow derived-dendritic 
cells (BM-DC).  
 
A 30 mer muc-1 peptide is designed.  In general, peptides are weak immunogen 
which require adjuvant activity to increase their immunogenicity. DC are 
considered as “natural adjuvant” because they are the most professional APC 
with exquisite capability to activate naive T cells.  To enhance the immunity 
induced by muc-1 peptide, the muc-1 peptide is loaded in vitro onto bone 
marrow-derived DC (BM-DC).  BM-DC can be generated in vitro by culturing 
BM in the presence of GM-CSF and IL-4.  BM-DC have been well documented 
to act as an efficient APC. Mice are then immunized with muc-1-pulsed BM-DC 
(muc-1/BM-DC) or muc-1 peptide. The ability of muc-1/BM-DC, compared to 
synthetic muc-1 peptide, to generate CTL response is investigated.  Therefore, 
using a well-established BM-DC system, the immunogenicity of the muc-1-












Figure 1.5  Immune competent of pNGVL3-hFLex plasmid DNA stimulated DC 
(hFlex-DC) 
 
Recently, it has been demonstrated that in mouse model, injection of human 
recombinant FL (hFL) in mice causes a significant increase in the numbers of 
myeloid-related and lymphoid-related DC in various organs. These in vivo 
generated DC provide an alternative source of DC. However, the potency of hFL-
induced DC to act as APC is not yet proven. In our system, DC are generated in 
vivo using pNGVL3-hFLex plasmid DNA encoding for human extracellular 
domain of human Flt-3 ligand (Flt-3L).  The plasmid DNA is delivered via a 
novel hydrodynamic-based tail vein injection to achieve high transgene 
expression. The expanded DC are purified (hFlex-DC) and their ability in antigen 
uptake, processing and presentation are examined and compared to BM-DC as 
described in Model 1. Most importantly, hFlex-DC are pulsed with muc-1 peptide 
(muc-1/hFlex) in vitro and mice are then immunized with muc-1/hFlex. The 
ability of muc-1/hFlex-DC to generate muc-1 specific CTL response is compared 
to muc-1/BM-DC. The ability of muc-1 pulsed hFlex-DC to generate muc-1 
specific CTL response form the basis for our subsequent studies. 
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Figure 1.6  In vivo stimulation of DC by pNGVL3-hFLex plasmid DNA and 
immunogenic peptides.  
 
After demonstrating the potency of hFlex-DC pulsed with muc-1 peptide in vitro 
(muc-1/hFlex-DC) to induce CTL response in mice, we then investigate the 
ability of the hFLex-DC to act as APC in vivo. Following DC expansion with 
pNGVL3-hFLex plasmid DNA delivered via novel hydrodynamic-based tail vein 
injection, muc-1 peptide is administered via various doses and immunization 
routes. This is based on our hypothesis where the expansion of DC in situ/in vivo 
will enhance antigen presentation activity and would subsequently increase the 
ability of the immunized host’s cellular immune responses to exogenous antigens. 























Figure 1.7  Investigation of immunogenicity of chimeric pNGVL3-hFLex-muc-1 
DNA vaccine.  
 
To mimic the peptide strategy as described in Model 3, a chimeric DNA vaccine 
encoding the extracellular domain of human Flt-3L ligated to the muc-1 epitope 
(pNGVL3-hFLex-muc-1) is constructed. Flt-3L within the chimeric vaccine 
functions to expand/recruit DC in situ/in vivo and secrete the muc-1 peptide. The 
potency of pNGVL3-hFLex-muc-1 DNA vaccine is examined via hydrodynamic-
based intravenous delivery system, mimicking strategy in Model 3.  Induction of 
muc-1 specific immunity and anti-tumor response is examined. DNA vaccine 
offers several advantages over peptide vaccine. The plasmid DNA is feasible for 
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Figure 1.8  Intramuscular immunization with pNGVL3-hFLex-muc-1 DNA 
vaccine.  
 
The potency of the chimeric DNA vaccine is also investigated via intramuscular 
immunization, a conventional DNA immunization route, in comparison to the 
novel hydrodynamic-based tail-vein injection as described in Model 4.  In 
addition, the chimeric DNA vaccine is delivered intramuscularly (A) with or (B) 
without the advance systemic DC expansion with pNGVL3-hFLex plasmid 
DNA. It is postulated that advance systemic DC expansion would enhance the 
potency of DNA vaccine.  Generation of muc-1 specific immunity and anti-tumor 






MATERIALS AND METHODS 
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2.1     Animals and cells lines 
Female C57BL/6 mice were purchased from the Animal Laboratory Unit of 
National University of Singapore and were used at 8-12 weeks of age.  The RMA 
(H-2b) lymphoma parental cell line and transfected muc-1+ RMA cells were gifts 
of Dr B. Acres (Transgene, Strasbourg, France).  All the cells lines or spleen cells 
were cultured in 5% CO2 incubator at 37oC unless otherwise stated. 
 
2.2  Peptides   
The synthetic 30-mer muc-1 peptide, employed in this study, has the amino acid 
sequence PDTRPAPGSTAPPAHGVTSAPDTRPAPGST and falls within the 
VNTR region of the muc-1 molecule [171-172].  A second peptide, derived from 
NP365-380 of the human influenza virus and has the amino acid sequence 
IASNENMETMESSTLE, was employed as a control [173].  The peptides were 
synthesized and obtained from Mimotopes, Clayton Victoria, Australia.  They 
were >95% in purity. 
 
2.3     Preparation of bone marrow-derived dendrites cells (BM-DC) 
2.3.1  Culturing of BM-DC 
DC were prepared from bone marrow cells essentially according to the 
procedures described by Inaba et al [174].  Briefly, bone marrow was flushed 
from the tibia and femur of C57BL/6 mice and depleted of erythrocytes with 
Tris-ammonium (Tris-NH4) (0.16 M NH4Cl, 0.17 M Tris-Cl in 9:1, pH 7.2) lysis 
buffer (0.1 ml packed cells/ml Tris-NH4).  The remaining cells were then cultured 
using complete RPMI media consisted of the RPMI 1640 medium (Life 
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Technologies, Grand Island, USA) supplemented with 100μg/ml streptomycin 
(Life Technologies, Grand Island, USA), 0.1 mM non-essential amino acids (Life 
Technologies, Grand Island, USA), 2mM glutamine, 1 mM sodium pyruvate, 
10% heat inactivated FBS (HyClone Laboratories, Utah, USA), 50μM 2ME, 
1000U/ml GM-CSF (BD Pharmingen, San Diego, USA) and 500U/ml IL-4  (BD  
Pharmingen, San Diego, USA).  At day 3 of culture, the non-adherent cells were 
gently removed and fresh medium with cytokines was added.  Fresh GM-CSF 
and IL-4 were added to the culture at every alternate day.  On day 10, non-
adherent and loosely adherent cells were harvested and subjected to purification.  
 
2.3.2   Purification of BM-DC 
DC were purified from the above harvested cells using CD11c+ micromagnetic 
beads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) following the 
suggested standard protocol.  For MACS separation, the cultured BM cells (5-8 
x107) were suspended in 400μl MACS buffer (0.5% FBS and 2mM EDTA in 
PBS, degassed).  Then, 100μl of MACS CD11c+ microbeads was added, mixed 
and incubated for 15 min at 4oC.  Meanwhile, the positive selection column (LS+ 
column) placed in the magnetic field of a MACS separator was equilibrated with 
MACS buffer.  The CD11c+-microbead-labbed DC were then loaded onto the 
LS+ column and washed 2 times (2x) with MACS buffer.   After that, the LS+ 
column was removed from the MACS separator and 3ml of MACS buffer was 
added onto the column.  Finally, the DC were flushed out from the column using 
the plunger supplied.  The magnetic separation steps were repeated to obtain > 
90% purity.  
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 2.3.3   Purity analysis of BM-DC by flow cytometry 
5 x 105 cells/100μl of purified BM-DC were incubated with appropriate dilution 
of FITC/PE-conjugated anti-mouse CD11c, CD86, CD80 and CD8 antibodies 
(BD Pharmingen, California, USA) in FACS buffer (1% FCS+ 0.1% NaN3 in 
PBS). Then, the cell suspension was incubated in the dark at 40C for 30 min. 
Following that, the cell suspension was washed by adding 1 ml of FACS buffer 
and centrifuged at 800 g for 5 min.  Finally, the cell pellet was re-suspended in 
400μl FACS buffer and ready for flow cytometry analysis using FACS Calibur 
(BD Pharmingen, California, USA).  
 
2.4    Wright-Giemsa staining 
Bone marrow cells or purified BM-DC were smeared on a clean microscope slide 
and allowed to air-dry.  The cells were fixed with methanol for 5 min and washed 
with PBS. The cells were stained using Wright-Giemsa Staining kit (Thermo 
Shandon, Pittsburg, USA).  
 
2.5      Preparation of muc-1 pulsed DC 
Purified DC were re-suspended in complete culture medium containing 60 μg/ml 
of the muc-1 peptide.  After incubating for 2h at 37oC, cells were washed five 
times with RPMI 1640 medium to remove the FBS prior to injection into mice. 
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2.6    Immunization protocol for peptide-based strategy 
2.6.1    Immunization of mice with muc-1-pulsed BM-DC and/or muc-
1 peptide 
Three different immunization protocols were employed.  The mice were 
immunized intravenously (i.v.) with muc-1 peptide or muc-1-pulsed BM-DC 
intraperitoneally (i.p.). Three separate groups of naive C57BL/6 mice were 
primed separately according to the following protocols.  For the first group of 
mice, they were immunized twice with 60μg of the muc-1 peptide each time and 
at 10d interval.  The second group of mice was primed with 60μg of the muc-1 
peptide followed by a second immunization with 1x106 muc-1 pulsed DC 10d 
later.  The third group of mice was immunized twice with 1x106 muc-1 pulsed 
DC each time and at 10d interval. Spleen cells were prepared from these 
immunized mice ten days after the second immunization and employed for the 
proliferation, cytokine and CTL assays. Day  
(d)
  d0           d10 d20 
 
 1st immunization 
 
2nd immunization CTL 
 
muc-1 peptide muc-1 peptideGp 1: 
 
muc-1pulsed BM-DCGp 2: muc-1 peptide 
 
 
Gp 3: muc-1pulsed BM-DC muc-1pulsed BM-DC
Figure 2.1  Immunization regimen with muc-1 pulsed BM-DC or muc-1 peptide. 
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2.6.2    Immunization of mice with muc-1 pulsed BM-DC or muc-1 
pulsed hFlex-DC 
Mice were injected with pNGVL3-hFLex plasmid DNA via hydrodynamic-based 
intravenous delivery system.  Spleen cells were harvested 10d after delivery of 
pNGVL3-hFLex plasmid DNA. Then, the CD11c+ splenic DC were purified as 
described above and pulsed with muc-1 peptide (hFlex-DC).  Mice were 
immunized twice at 10d interval either with muc-1 pulsed BM-DC or muc-1 
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2.6.3    Immunization of mice by in vivo stimulation with pNGVL3-
hFLex plasmid DNA and muc-1 peptide 
Mice were first inoculated with pNGVL3-hFLex plasmid DNA via 
hydrodynamic-based intravenous delivery system to expand DC in vivo.  At d10, 
mice were given 60μg or 300μg muc-1 peptide intravenously or intrasplenically.  
 
d0 d7 d17




2nd immunization (i) CTL assay 
(ii) Challenged with RMA-muc-1  




muc-1 peptide pNGVL3-hFLex     Gp 1: 
    Gp 2:  muc-1 peptide pNGVL3 
 
 
  Gp 3: pNGVL3-hFLex NaCl
Figure 2.3  Immunization regimen with pNGVL3-hFLex plasmid DNA and 
immunogenic peptide (muc-1 peptide).   
 
2.7    In vivo delivery of muc-1 peptide 
2.7.1    Intrasplenic injection of muc-1 peptide 
 
All the scissors and forceps were sterilized.  Mice were first anesthetized with 
ketamine/xylaxine mixtures (10 and 2mg/kg). The mice were disinfected with 
70% ethanol during the surgical procedure. Then, the spleens of anesthetized 
mice were exposed to allow direct intrasplenic injection of muc-1-containing-
PBS (60μg muc-1peptide/100μl PBS) with a 271/2 gauge needle. Finally, the 
skin wound closure was done using stainless-steel wound clips [175]. 
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2.7.2    Intravenous delivery of muc-1 peptide 
60μg or 300μg of muc-1 peptide in 200μl PBS was delivered intravenously via 
conventional tail-vein delivery method. 
 
2.8    Preparation of spleen cells 
For obtaining single cell suspension, harvested spleen was meshed with a 3 ml 
syringe’s plunger in a petri dish containing PBS.  The spleen cells were then 
collected and centrifuged at 800 g for 5 min.  The spleen cells pellet was then re-
suspended with 1ml Tris-NH4 lysing buffer (0.1ml packed cells/ml) and 
incubated for 2 min at RT to lyse the red blood cells.  The lysis reaction was 
quickly stopped by addition of 10ml of complete RPMI 1640 into the cell 
suspension.  The spleen cells were then centrifuged at 800 g for 5min followed by 
3 additional washes with PBS. They were now ready for use in proliferation, 
cytokine, CTL and CTLp assays. 
 
2.9    Proliferation assay 
Spleen cells (3x105 cells) prepared from the immunized animals were incubated 
with 10 μg/ml of the muc-1 peptide, in triplicates, in 96-well flat-bottom tissue 
culture plates for a period of 4d at 370C.  At the end of day 3, 1 μCi [3H]TdR 
(Amersham Life Science, Uppsala, Sweden) was added into each well and 
incubated for an additional 16h.  Incorporating of [3H]TdR into DNA of 
proliferating  cells was analysed by harvesting the the cells in the plates and then 
measuring the radioactivity in Wallac 1450 Microbeta TriLux liquid scintillation 
counter (EGΣG Life Sciences, Turku, Finland). 
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2.10    Purification of allogeneic (H-2d) T cells  
2.10.1   Preparation of nylon wool 
Nylon wool was saturated with excess volume of 1% HCl in a 5L beaker and 
boiled for 5-10 min to remove contaminants.  It was then allowed to cool and the 
liquid was poured off. The nylon wool was squeezed to release trapped fluid and 
washed with ddH2O for at least 10x to remove residual HCl.  The nylon wool was 
dried at RT and 0.8-1.0 g of nylon wool was weighed.  The nylon wool was 
fluffed by combing until it was free of knots.  The fluffed nylon wool was then 
inserted into syringe. The plunger was later used to compact the nylon wool and 
the column was sent for autoclaving. 
 
2.10.2   T cell isolation from non-adherence to nylon wool 
The sterilized nylon wool column was clamped to a stand and an adjustable 
opening was attached to the column.  The column was equilibrated by running 
through 30-50 ml of 37oC pre-warmed RPMI-5 (RPMI 1640 medium with 5% 
heat inactivated FBS).  The trapped air bubbles were removed by firmly tapping 
on the sides of the column until no white (dry) areas were visible.   The nylon 
wool was then tamped down with a sterile pipet to get rid of any additional 
trapped air.  The column was covered with 2-3 ml of 37oC RPMI-5 and allowed 
to incubate at 37oC for 45 min.  After that, the medium was allowed to drain 
completely and spleen cell suspension (< 5x107 cell/ml) was passed through the 
column.  0.5 ml of 37oC RPMI-5 was added to make sure all the cells penetrate 
through the column.  Following on that, 2-3 ml of 37oC RPMI-5 was added to 
cover the column and the column was incubated in an upright position at 37oC for 
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45 min.  After the incubation, the column was filled with the 37oC RPMI-5 and 
immediately the first 15 ml of effluent cells was collected for best T cell 
enrichment.  Then the eluted cells were centrifuged at 800 g for 10 min.  The 
purity of the cells was accessed by FACS analysis using anti-mouse CD3-FITC 
antibody.  The T cells were > 90% in purity. 
 
2.11    Allostimulation Assay 
3 x105 allogeneic (H-2d) nylon wool purified T cells, >90% purity, were seeded 
into wells of flat-bottomed 96-well microtiter plates. Bone marrow-derived or 
pNGVL3-hFLex-derived DC (H-2b) preparations were irradiated with 2,500 Rad 
137Cs generated-gamma radiation (Nordion Corp., Kanata, Canada) were added to 
achieve various responder : DC stimulator ratios. Control groups included: 
irradiated DC preparations cultured without responder cells; responder cells 
cultured without DC preparations. Each group was cultured in triplicate.  The 
proliferative response was measured after 4d of incubation as described above. 
 
2.12   IL-2-conditioned media  
2.12.1   Preparation of IL-2 conditioned media (Con-A-sup)  
 
Spleen of Wistar rat was harvested and meshed to prepare a single cell 
suspension. The red blood cells were removed using Tris-NH4Cl and the 
splenocytes were re-suspended in complete RPMI 1640 medium at a cell density 
of 5x106 cells/ml in a T-175 tissue culture flask.  Concavalin-A (Con-A) (Sigma, 
Chemical Co, St Louis, USA) at a final concentration of 5μg/ml was added to the 
splenocytes and cultured for 48 hr at 37oC.  After 48 hr of incubation, the cell-
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free culture supernatant (S/N) was harvested by centrifuged twice at 1200 g for 
15 min.  The cell-free S/N was transferred into a sterile 50 ml centrifuge tube.   It 
was then added with methyl-α-pyranoside (Sigma, Chemical Co, St Louis, USA) 
at a final concentration of 0.2 g/ml.  The cell-free S/N was filtered, aliquot and 
frozen at –20oC.    
 
2.12.2  Determination of optimal IL-2-conditioned media (Con-A-sup) 
concentration for CTLL-2 cell line  
To investigate whether 2% Con-A-sup is sufficient to maintain the growth of 
CTLL-2 cell line, a serial dilution of Con-A ranging from 20% to 0.625% was 
made.  The growth of CTLL-2 cell line is dependent on exogeneous IL-2.  2 x 104 
CTLL-2 cells were plated on a 24-well plate and Con-A-sup ranging from 20% to 
0.625% was added to the cells and incubated for 48 hr.  The viability of CTLL-2 
cells was counted on haemocytometer using trypan blue exclusion assay.  A 2% 
Con-A sup is expected to give 100% viability on CTLL-2 cells.  
 
2.13   CTL assay 
2.13.1   Preparation of effector cells  
Spleen cells were prepared from the immunized mice.  The spleen cells were 
either employed directly as effector cells in 51Cr-release assay or were further 
stimulated in vitro with 10μg/ml muc-1 peptide in U-bottom micro-titer plates for 
6d before harvested as effector cells for the 51Cr-release assay.   
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2.13.2   Preparation of Chromiun-51 (Cr-51) labeled target cells  
Spleen cells (2x106) were cultured with 5μg/ml ConA in 24-well plates for 2d at 
37o C.  The blast cells obtained following stimulation were then incubated for 12h 
either with 60μg/ml of the muc-1 peptide or the flu peptide.  Pelleted 10-100 x 
105 peptide-pulsed blast cells, RMA or muc-1+-RMA cells were labeled by 
incubating with 50μCi of Na251CrO4 (Amersham Life Science, Uppsala, Sweden) 
for 60 min at 37o C followed by extensive washing (5x) with RPMI 1640 
supplemented with 2% FBS.  These labeled peptide-pulsed blast spleen cells, 
RMA and muc-1+-RMA cells were then employed as target cells for the 51Cr-
release assays.   
 
2.13.3   Cr-51 release assay 
51Cr-labeled target cells (3 x 103 or 1x 104 cells) and effector spleen cells at 
various ratios were re-suspended in culture medium and added into the 96-well, 
U-bottom plates.  The plates were centrifuged at 100g for 3 min to initiate cell 
contact and then incubated for 6h at 37o C.  After incubation, the supernatants 
were collected and the amount of radioactivity was quantified using scintillation 
counter (EGΣG Life Sciences, Turku, Finland).  
 
2.14   Determination of CTLp frequency 
For each of the cell preparation for the determination of the CTLp frequencies 
were to be determined, a minimum of 32 replicates including at least 6 responder 
doses (ranging from 1x103 to 5x105 responder cells per well) were cultured in U-
bottom micro-titer plates.  Irradiated C57BL/6 spleen cells (5x105 cells) were 
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added as APC, in complete RPMI1640 medium supplemented with 10μg/ml 
synthetic muc-1 peptide and 2% Con-A-sup.  After culturing for 6d, each micro-
culture was assayed for cytotoxicity by replacing 0.1ml of the culture media with 
0.1ml of fresh culture media containing either 104 of 51Cr-labeled RMA parental 
cells or the muc-1-transfected clone as target cells.  Wells would be considered 
positive for CTL activities if they yielded specific 51Cr release 3SD above the 
mean 51Cr release of 104 responder cells cultured alone, cultured with 5x105 
stimulators cells, cultured in the presence of peptide or cultured with 2% Con-A-
sup.  A linear relationship could be obtained between the dose of responder cells 
and the frequency of negative wells on a logarithmic scale.  The CTLp 
frequencies were then determined as the inverse of the responder cell dose 
required for the generation of 37% wells that were negative for CTL activities 
[176-178].  
 
2.15  Detection of anti-muc-1 antibody by enzyme-linked 
immunosorbent (ELISA) assay  
To detect the presence of anti-muc-1 antibodies, an ELISA was established.  
Briefly, wells of 96-well micro-titer plates were coated with a solution containing 
10μg/ml of the muc-1 peptide and 2% bovine serum albumin (BSA) to reduce 
non-specific binding.  50μl of sera obtained from immunized mice were 
appropriately diluted and added to the wells.  After incubating for 1h at RT, 
sheep anti-mouse immunoglobulin conjugated to horseradish peroxidase 
(Amersham Life Science, Uppsala, Sweden) was added and incubated at RT for 
an additional hour.  The assays were subsequently developed by the addition of 
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50μl of 0.03% 2, 2’-azino-di(3-ethylbenzthiazoline sulphonate (Sigma Chemical 
Co, St Louis, USA), 0.02% H2O2 (Merck, Darmstadt, Germany) in 0.1M citrate 
buffer, pH 4.25.  The mixture was incubated for 20-30 min at RT until the desired 
intensity was achieved and the absorbance at 405 nm determined using a ELISA 
plate reader.  Normal mouse serum (NMS) was employed as the negative control. 
 
2.16   Measurement of IL-2 Using CTLL-2 line 
5 x105 spleen cells prepared separately from the immunized mice were cultured 
in the presence of 10μg/ml of the muc-1 peptide.  After 48h, the culture 
supernatant was collected and employed to set up the proliferation assays with 
the IL-2-dependent CTLL-2 cells.  5x103 CTLL-2 cells were cultured in the 
presence of serial diluted culture supernatant in 96-well U-bottom plates. A 
standard curve was prepared using 0.5-10 U recombinant IL-2 (BD Pharmingen, 
California, USA).  After 24h, [3H]TdR was added into the cells and then 
incubated for additional 12h.  The cells were harvested and the amount of 
radioactivity incorporated was determined.  
 
2.17   Determination of IFN-γ and IL-10 concentration by ELISA 
Splenocytes obtained from the immunized mice were cultured at 5 x105cells/well 
in the presence of the muc-1 peptide.  Culture supernatants were collected 
following 3d incubation.  For ELISA, 50μl of the culture supernatant was added 
to ELISA plates coated with 4μg/ml of rat anti-mouse IFN-γ or rat anti-mouse IL-
10 antibody (BD Pharmigen, San Diego, California) and incubated at RT for 1h.  
The plates were then washed with Tween-20-PBS and incubated at RT for 1h 
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with secondary biotinylated rat antibody against mouse IFN-γ or mouse IL-10 
(1μg/ml).  After washing the plates, 50μl of avidin-peroxidase (Sigma Chemical 
Co, St Louis, USA) was added and incubated for 30 min at RT.  The plates were 
further washed and then developed using the 2, 2’-azino-di(3-ethylbenzthiazoline 
sulphonate substrate (Sigma Chemical Co, St Louis, USA).  The absorbance at 
405nm was determined using ELISA plate reader after incubation for 30 min at 
RT.  Recombinant mouse IFN-γ and mouse IL-10 was employed as standards to 
generate the standard curve. 
 
2.18   Gene delivery system 
2.18.1   Hydrodynamic-based tail-vein injection of plasmid DNA 
The injection was carried out as described by Liu et al [179].  The mice were first 
heated with a lamp for about 5-10 min to dilate the blood vessels.  Then, 10-20 
μg plasmid DNA suspended in 1.5 ml of 0.9% NaCl solution was injected into 
the tail-vein of mice over 10 second.  The injection was carried out using 271/2 
gauge needle and 3ml syringe.   
 
2.18.2   Intramuscular injection (i.m.) of plasmid DNA 
Intramuscular injection (i.m.) [180] was done using a 271/2 gauge needle.  10μg 
or 20μg plasmid DNA was diluted in 100μl PBS and injected within the thigh 
area of the right leg of the mouse.  
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2.19  Molecular Cloning of pNGVL3-Flex-muc-1 and pNGVL3-
muc-1 DNA vaccines   
2.19.1   Construction of chimeric pNGVL3-FLex-muc-1 DNA vaccine 
2.19.1.1   Restriction of pNGVL3-hFLex and pNGVL3-hFLex-Trail 











 Figure 2.4 Map of pNGVL3-hFLex plasmid DNA (adapted from The 
University of Michigan Vector Core)  
  
The pNGVL3-hFLex plasmid contains the extracellular domain (secreted form) 
of the human Flt-3L gene has been described previously [181]. Plasmid DNA 
containing gene encoded for extracellular domain of Flt-3L (FL) which was fused 
with human Trail (pNGVL3-hFLex-TRAIL) was a gift from Dr. Wu Xia Feng, 
National Cancer Center.  To remove the Trail fragment, the plasmid DNA was 
double-digested with restriction enzyme Nhe I and Bam HI.  On the other hand, 
to remove FL fragment, the pNGVL3-FL plasmid DNA was restricted with Sal I 
and Bam HI.   
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The restriction mixture was as follow: 
Plasmid DNA (2µg)     2.0    µl 
Bam HI     1.0    µl 
NheI or Sal I     1.0    µl 
BSA (100X)     0.2    µl 
BamHI buffer (10X)     2.0    µl 
ddH2O   13.8    µl 
Total    20.0   µl 
 
The restriction mixture was incubated overnight at 37oC.  All the restriction 
enzymes are from New England Biolabs, UK.  
 
2.19.1.2  Purification of restricted pNGVL3 plasmid DNA using 
QIAquick Gel Extraction Kit  
The restricted FL-TRAIL plasmid DNA (plasmid DNA vector) was run on 1% 
agarose gel and the restricted DNA vector was excised from the gel using a clean 
scalpel. The restricted DNA vector was extracted from the excised gel according 
to the standard protocol provided by QIAquick gel extraction Kit (Qiagen, 
California, USA).  The excised gel fragment was weighed and the appropriate 
amount of buffer QG was added (3 volumes of Buffer QG to 1 volume of gel).  
Following that, the above mixture was incubated at 50oC for 10 min to dissolve 
the gel fragment and 1 gel volume of isopropanol was added.  The above mixture 
was then loaded onto QIAquick column and spun for 1 min. Then, the QIAquick 
column was washed with 0.75 ml buffer PE and centrifuged for 1 min. Finally, 
the DNA was eluted by adding 30μl ddH2O to the column and spun for 1min. 
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The purified DNA was then used for the subsequent cloning procedures. All 
centrifugation was carried out at 10000 g in a tabletop microcentrifuge.  
 
2.19.1.3  Removal of 5’ phosphate group from the plasmid vector 
In order to prevent the self-ligation of the plasmid DNA vector, the above gel-
purified and restricted plasmid DNA vector was subjected to calf intestinal 
alkaline phosphatase (CIP) treatment (New England Biolabs, UK). The CIP 
catalyzes the hydrolysis of 5’ phosphate residues from the plasmid DNA vector.  
The following reaction mixture was prepared and incubated at 37oC for 45 min.  
Following that, the CIP reaction mixture was cleaned up using QIAquick PCR 
purification kit (Qiagen, California, USA) following the manufacturer’s 
instruction.  The plasmid DNA vector was ready for use in the subsequent 
ligation reaction.  The CIP reaction was as follow: 
Plasmid DNA vector 17.0    μl
CIP     1.0    μl
Buffer (10X)     2.0   μl
Total volume   20.0   μl
 
2.19.1.4   QIAquick PCR purification kit 
The purification procedure is according to manufacturer’s recommendation. 5 
volumes of buffer PB (composition) was added to the CIP reaction mixture, 
described previously, and mixed by vortexing.  The reaction mixture was then 
loaded onto the QIAquick column and centrifuged. The column was washed with 
0.75 ml buffer PE and centrifuged. Finally, the DNA was eluted with ddH2O by 
centrifugation.  All the centrifugation was carried out at 10000 g for 1 min.  
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 2.19.1.5   Chemical synthesis and annealing of synthetic muc-1 
oligonucleotides 
Forward(ccggacaccaggccggccccgggctccaccgcccccccagcccatggtgtcacctcggccccgga
caccaggccggccccgggctccacc) and reverse muc-1 single-stranded (s/s) synthetic 
oligonucleotides containing the Nhe I and Bam HI restriction site was chemically 
synthesized (Invitrogen, California, USA). The forward and reverse muc-1 (s/s) 
synthetic oligonucleotides were annealed to become the double-stranded (d/s) 
oligonucleotide following the reaction: 
Forward oligonucleotide 100 nmole/ml 
Reverse oligonucleotide   100 nmole/ml 
10x annealing buffer  1X 
DEPC-treated H2O  Appropriate volume
Total  10  μl 
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The mixture was incubated at 65oC for 10 min in a water bath and then allowed 
to cool slowly at room temperature (1-2 hr).  The annealed product was stored at 
–20oC for the subsequent cloning procedure.   
 
2.19.1.6   Ligation  
Ligation mixture of the plasmid DNA vector and the double-stranded (d/s) muc-1 
oligonucleotide was prepared as below.   
Plasmid DNA vector appropriate volume 
Insert (annealed d/s MUC-1 oligonucleotide) appropriate volume 
Ligase buffer  2.0  μl 
T4 DNA Ligase  1.0  μl 
50% PEG  2.0  μl 
ddH2O  appropriate volume 
Total  20.0  μl 
 
In the ligation mixture, the vector and insert molar ratio was maintained at 1:3 
and the ligation mixture was incubated at 16oC overnight. The Ligase is from 
New England Biolabs, UK. 
 
2.19.1.7  Preparation of transformation competent DH5α E.coli 
(Rubidium Chloride) 
A single colony was inoculated in 5ml LB and cultured overnight at 37oC in a 
shaker.  Then, 1 ml of the overnight bacterial culture was inoculated into 100 ml 
LB.  The bacterial culture was incubated at 37oC with aeration to A600=0.48.  
Upon achieving A600=0.48, the bacterial culture was placed on ice for 15 min in 
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the cold room.  The bacterial cells were spun at 5000g for 5 min at 4oC (brake 
was not applied when stopping the centrifugation). The supernatant was 
discarded and re-suspended in 0.4 volume (40ml) TfbI (30mM potassium acetate, 
100mM rubidium chloride, 10mM calcium chloride, 50mM manganese chloride 
and 15%v/v glycerol).  The bacterial cells suspension was left on ice for 15 min. 
Following that, the bacterial cells were centrifuged at 5000g for 5 min at 4oC.  
The supernatant was discarded and the cells pellet was re-suspended in 0.04 vol 
(4ml) TfbII (10 mM MOPS, 75 mM calcium chloride, 10 mM rubidium chloride 
and 15%v/v glycerol).  The competent cells were then aliquoted into pre-cooled 
1.5ml eppendorf tube (200μl/tube) and snapped freeze in liquid nitrogen.  They 
were stored in –80oC until further usage. 
 
2.19.1.8  Transformation  
8 μl of the above mentioned ligation mixture was added into 100μl of chemically 
competent DH5α E.coli bacterial cells and mixed gently. The mixture was 
incubated on ice for 30 min. The bacterial cells were then heat-shocked at 42oC 
for 45s without shaking and immediately transferred to ice. 1ml of SOC (trytone 
2%, yeast extract 0.5%, NaCl 10mM, KCl 2.5mM, MgCl2 10mM, MgSO4 10mM, 
glucose 20 mM, filtered) was added to the mixture and incubated at 37oC for 1 hr 
with shaking (250rpm). After that, the bacterial cells were spun at 2000 rpm for 2 
min and the excess SOC is removed, leaving 20-30μl in the tube. The bacterial 
cells pellet was re-suspended and then spread on a pre-warmed kanamycin 
selective LB agar plate and incubated at 37oC overnight.   
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2.19.1.9  Analysis of MUC-1+ bacterial clones  
The bacterial colonies were selected and subjected to PCR analysis.  The 
bacterial clones were picked with sterile pipet tips and dapped into 20 μl ddH2O 
in the corresponding PCR tube.  The bacterial mixtures were then heated at 94oC 
for 2 min.  Then, a 50 μl of PCR reaction was established. The muc-1+ PCR 
positive bacterial clones were then dapped into 3 ml of kanamycin-containing LB 
broth and cultured for 12 hr. The plasmid DNA was isolated with QIAprep Spin 
Miniprep Kit.  The isolated plasmid DNA was then subjected to restriction 
analysis using Bam HI and Nhe I restriction enzyme. Finally, the muc-1+ bacterial 
clones were confirmed by DNA sequencing.   
 
2.19.1.10  PCR reaction 
PCR reaction was established as follows: 
 
Template (10ng-200ng) variable  
Forward primer (10µM) 1 µl 
Reverse primer (10µM) 1 µl 
Taq buffer (10x) 5 µl 
MgCl2 (25 mM) 4 µl 
dNTP mix (10 mM) 4 µl 
Taq polymerase (5U/µl) 0.5 µl 
ddH2O variable 
Total volume 50 µl 
 
The PCR reaction was carried out in a MJR PTC-100 thermocycler with the 
following programme:  
 
Step 1 2 min at 94oC 
Step 2 1 min at 94oC: 30s at 55oC: 30s at 72oC  (for 25-35 cycles) 
Step 3 10 min at 72oC 
Step 4 18 hr at 4oC  
 
Taq polymerase is from Promega, Madison, USA.  
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2.19.1.11  QIAprep Spin Miniprep Kit  
 
The procedure was suggested by manufacturer.  3ml of overnight bacterial 
cultures was pelleted at 2000 rpm for 10 min.  250 μl of RNase-A-containing 
buffer P1 was added to the pelleted bacterial cells and mixed thoroughly until no 
visible cell clumps.  250 μl of buffer P2 was then added and mixed gently by 
inverting the tube 4-6 times.  350 μl of buffer N3 was added and mixed gently 
and thoroughly.  The mixture was centrifuged for 10 min at 13000 rpm in a table-
top microcentrifuge.  Then, the supernatant was applied to the QIAprep spin 
column and centrifuged for 30-60s. The flow-through was discarded and the 
column was washed with buffer PB and centrifuged for 30s. The column was 
then washed with 0.75 ml buffer PE and centrifuged for 30s. The flow-through 
was discarded and the column was centrifuged for an additional 1 min to remove 
residual wash buffer.  Finally, the DNA was eluted from the column with 50μl 
sterile ddH2O. 
 
2.19.2   Construction of pNGVL3-muc-1 DNA vaccine 
In brief, the muc-1 DNA sequence was PCR from the pNGVL3-hFLex-muc-1 
plasmid DNA using the following primers: 
Primer 1: 5' GC GTC GAC GCC ACC ATG CCG GAC ACC AGG CCG GCC 3' 
 
Primer 2: 5' GC GGA TCC CTA GGT GGA GCC CGG GGC CGG CCT GGT 3' 
 
The Sal 1 restriction sequences, kozak sequences and start codon were 
incorporated into primer 1. In contrast, BamH1 recognition sequences were 
incorporated into primer 2.  The PCR product was then cloned into TOPO 
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cloning vector as recommended by the kit (Invitrogen, California, USA).  The 
muc-1+ bacterial clones were screened with PCR and enzyme restriction.  The 
muc-1 restricted DNA fragment from the TOPO cloning vector was then cloned 
into pNGVL3 vector restricted with Sal 1 and Bam H1 as described above.  The 
pNGVL3-muc-1 plasmid DNA was confirmed by DNA sequencing.  
 
2.20    In vitro transfection 
2 x105 of A549 cells were plated overnight onto 6-well culture plate or coverslip 
which was placed in a petri dish.  The cells were then transfected with pNGVL3-
hFLex, pNGVL3-hFLex-muc-1 and pNGVL3-muc-1 plasmid DNA using 
Lipofectamine transfection kit (Invitrogen, California, USA) according to the 
manufacturer’s instruction.  Briefly, 3μg plasmid DNA was mixed with 8 μl Plus 
reagent and 100 μl Optimem (Invitrogen, San Diego, USA) for 15 min. 
Meanwhile, 15μl of lipofectamine was added to 100 μl Optimem.  The above two 
mixtures were added together and incubated for another 15 min at RT.  Next, the 
mixture was added to the cells and incubated for 4 hr at 37oC before the addition 
of 20% FBS-supplemented RPMI 1640 culture medium. The cells were then 
analysed for positive transfection using immunofluorescence staining and 
Western blot analysis. 
 
2.21   Isolation of plasmid DNA-EndoFree Plasmid Maxi kit 
 
Endotoxin-free plasmid DNA was purified using the EndoFree Plasmid Maxi Kit 
(Qiagen, California, USA) with all the necessary reagents and buffers provided 
by the kit. The procedure of plasmid DNA isolation is according to the 
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manufacturer’s instruction.  In brief, 2ml of starter bacterial culture was 
inoculated to 250 ml LB. The bacterial culture was grown at 37C for 16 hr with 
vigorous shaking (~250 rpm).  After overnight culture, the bacterial cells were 
harvested by centrifugation at 6000 g for 15 min at 4C.  Then, the bacterial pellet 
was re-suspended in 10 ml resuspension buffer P1 (50mM Tris-Cl, pH 8.0; 10 
mM EDTA, 100 μg/ml RNase A) and mixed thoroughly.  10 ml of lysis buffer P2 
( 200 mM NaOH, 1% SDS) was then added and mixed gently but thoroughly by 
inverting 4-6 times, followed by incubation at RT for 5 min.  Following on that, 
10 ml chilled neutralization buffer P3 (3.0M Potassium acetate, pH5.5) was 
added and mixed immediately and the cell lysate was then poured into the barrel 
of the QIAfilter cartridge and incubated at RT for 10 min.  Then, the cell lysate 
was filtered into a 50-ml tube by inserting a plunger into the QIAfilter cartridge.  
2.5 ml buffer ER was added to the filtered lysate and incubated on ice for 30 min 
to remove endotoxin.  Meanwhile, QIAGEN-tip 500 column was equilibrated and 
then the above filtered lysate was allowed to pass through the column.  The 
column was washed with 2x 30 ml buffer QC (1M NaCl; 50 mM MOPS, pH7.0; 
15% isopropanol; 0.15% triton-X-100). The plasmid DNA was then eluted with 
15ml buffer QN (1.6M NaCl, 50mM MOPS, 15% isopropanol)  It was then 
precipitated with isopropanol and followed by centrifugation immediately at 
15,000 g for 30 min at 4C.  The DNA pellet was washed with endotoxin-free 




2.22    UV spectrophotometric quantitation of DNA 
The DNA sample was diluted appropriately in ddH2O and the absorbance at 
260nm and 280nm was measured using a spectrophotometer.  The ratio of 
A260/A280 gives an indication of the purity of the DNA sample whereas A260 
allows the calculation of the concentration of DNA sample. The DNA sample is 
considered pure if the ratio is between 1.8 and 2.0. 
 
2.23   Electrophoresis of DNA and PCR product 
The plasmid DNA or PCR product was visualized with agarose gel (1-2%) 
electrophoresis to determine the size and purity of the DNA or PCR product. 100 
bp DNA and 1 kb DNA ladder (New England Biolabs, UK) were used to 
determine the size of plasmid DNA and PCR product. 
 
2.24   Immunofluorescence staining for confocal microscopy 
As described in section earlier, transfected A549 cells on coverslip were fixed 
with methanol at -20oC for 5 min.  The cells were washed 3x with PBS then 
blocked with blocking buffer (1% BSA, 0.1% Triton-X 100, 10% normal goat 
serum and 0.02% sodium azide in TBS) for 1 hr at RT.  After that, rabbit anti-FL 
(Chemicon, California, USA) and mouse anti-muc-1 antibody (BD Pharmingen, 
California, USA) at a final concentration of 0.5 μg/ml was added and incubated 
for 1hr at RT.  Later, the cells were washed 3x with TBS (10 mM Tris-base, 150 
mM NaCl) and incubated with Alexa Fluor® 594 conjugated-anti-rabbit-IgG and 
Alexa Fluor® 488 conjugated-anti-mouse-IgG (Molecular Probes, Eugene, USA) 
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for 45 min. Finally, the cells were washed 3x with TBS and rinsed with water 
before mounting and observed under confocal microscope (Carl Zeiss, Germany).  
 
2.25   Determination of protein molecular weight by Western Blot 
Transfected cells were then lysed in single detergent lysis buffer (50mM Tris-
HCl, 150mM NaCl, 1% Triton-X 100,  1% NaN3). The protease inhibitor cocktail 
(Roche, Mannhein, Germany) was also added to the single lysis buffer. The cell 
lysate was diluted with 5x SDS sample buffer (10% w/v SDS; 20% v/v glycerol; 
0.2 M Tris-HCl, pH6.8; 0.05% w/v bromophenol blue and 10mM DTT) and 
heated at 95oC for 5 min and later subjected to 12% SDS-PAGE using a standard 
procedure.  After gel electrophoresis, the proteins were electrophoretically 
transferred onto nitrocellulose membrane using Semidry Electroblotter (Bio-Rad 
Lab, California, USA).  Non-specific protein binding sites were blocked by pre-
incubating with blocking buffer (BB) (5% skimmed milk in 0.5% Tween-TBS) 
for 1 hr, RT. Then, the membrane was incubated with 0.5μg/ml mouse anti-muc-
1 monoclonal antibody (BD Pharmingen, California, USA) and 0.5 μg/ml goat 
anti-Flt-3 polyclonal antibodies (Santa Cruz, California, USA) in BB for 1hr at 
RT.  The membrane was then washed three times using 0.5%Tween-TBS buffer.  
The membrane was later incubated with HRP-conjugated donkey anti-goat IgG 
(Santa Cruz, California, USA) or goat anti-mouse IgG (Santa Cruz, California, 
USA) in BB for 45 min, RT.  The membrane was washed extensively and 
incubated with chemiluminescent substrate solution (Pierce, Illinois, USA) for 
3min and then subjected to autoradiography.  
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2.26   Collection of mouse sera and determination of FL protein in 
sera 
After hydrodynamic-based tail-vein gene delivery of FL and F-muc-1, the level 
of FL protein secreted into mice sera was measured by anti-FL ELISA detection 
kit (R&D Systems, Minneapolis, USA).  Blood of mice after plasmid DNA 
delivery was collected.  The blood sample was first allowed to clot at RT for 1hr 
and then allowing further clotting at 4OC for 4hr. The clotted blood sample was 
then subjected to centrifugation at 4oC, 6000g, 10 min. The sera was then 
harvested and frozen at -20oC.   
 
2.27   Preparation of muscle tissues 
Muscle tissues around the intramuscular injection site (i.m.) were harvested at 
various time points post-injection. The harvested muscle tissues were 
homogeniased and lysed with single detergent lysis buffer.  The muscle lysate 
was then subjected to anti-Flt-3L ELISA assay to determine Flt-3L concentration.  
 
2.28  Immunization of mice with pNGVL3-Flex-muc-1 and 
pNGVL3-muc-1 DNA vaccines via hydrodynamic-based tail vein and 
intramuscular immunization 
Different immunization protocols were employed.  Separate groups of naive 
C57BL/6 mice were primed separately according to the following protocols. The 
mice were either immunized with 10μg (i.v.) or 20μg (i.m.) of the pNGVL3-
Flex-muc-1 plasmid DNA at 10d interval.  Spleen cells were prepared from these 
immunized mice 10d after the last immunization and employed for the 
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proliferation, cytokine and CTL assay. Control plasmid DNA: pNGVL3-hFLex 
or pNGVL3-muc-1 plasmid DNA.  
 
 






(i) Challenged with RMA-muc-1






Figure 2.5  Intramuscular immunization with pNGVL3-hFLex-muc-1 DNA 
vaccine. 1st immunization was done intravenously via hydrodynamic-based tail 
vein injection and the subsequent immunizations were done intramuscularly. 
 
 
2.29   Tumor protection assay 
In order to examine the ability of immunized mice to protect against tumor, the 
immunized mice were challenged with RMA/muc-1 or RMA parental tumor 
cells.  5 x105 RMA/muc-1 or RMA parental tumor cells were injected 
subcutaneously (s.c.) into group of ≥ 5 mice.  The tumor growth was monitored 
over time.  The perpendicular diameter (d) of tumor size was measured using a 
caliper vernier.  The tumor size is the product of two perpendicular diameter. 
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2.30    Immunohistochemistry (IHC) of muscle sections 
Muscle tissues adjacent to the plasmid inoculation of pNGVL3-muc-1 or 
pNGVL3-hFLex-muc-1 plasmid DNA were harvested and snapped frozen in 
nitrogen-cooled isopentane.  The frozen tissues were later subjected to cryostat 
sectioning.  Serial of 10 μm thick frozen muscle sections were adhered to poly-L-
lysine coated slide (Sigma Diagnostic, St Louis, USA) and kept at –80oC until 
further analysis.  Slides were fixed in –20oC-cooled acetone for 2 min, air-dried 
and washed with PBS to remove embedding medium.  The muscle sections were 
first incubated with 0.3% H2O2 in PBS for 80 min and then rinsed 3x with PBS.  
Following that, the sections were blocked with 10% goat serum in PBS for 1 hr 
and rinsed once with PBS.  100μl of anti-mouse CD11c, CD3e (e-Biosciences, 
California, USA) and CD8α (Pharmingen, California, USA) antibodies 
(10μg/ml) in 0.5% goat-serum in PBS was directed added onto muscle sections 
and incubated at RT for 2 hr.  The slides were washed 3x with PBS before 
incubating with 100μl of biotin-conjugated anti-hamster secondary antibodies 
(10μg/ml) for 45 min at RT.  The slides were then washed 3x with PBS and 
incubated with streptavidin-peroxidase (Pharmingen, CA, USA) for 30 min at 
RT.  After washing 3x with PBS, the antigen-antibody reaction was developed 
using 3,3’-diaminobenzidine (DAKO, CA, USA). The muscle sections were 
stained with Harris Hematoxylin (Sigma, CA, USA) for nucleus visualization.  
 
2.31   Hematoxylin staining  
50 μl of Harris Hematoxylin was added onto the muscle sections and incubated 
for 10 min at RT.  The slides were washed under a running tap water for 5 min 
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and rinsed with PBS.  Then, the muscle sections were dehydrated by dipping the 
slides 2x with 95% and 100% ethanol, respectively.  The slides were cleaned in 









3.1  Generation of potent and specific cellular immune responses 
via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA 
and immunogenic peptides (Published in Gene Therapy,2002) 
3.1.1  Generation of bone marrow-derived DC (BM-DC) 
Harvested bone marrow (BM) cells were cultured in the presence of GM-CSF 
and IL-4 for 10d to generate DC.  The phenotypes of BM cells before culture (d0) 
and after culture with GM-CSF and IL-4 (d5,d7 and d10) were shown in Table 
3.1.1.  At d7 or d10, non-adherent cells from the culture were harvested and 
purified using CD11c+ microbeads.  The purified BM-DC were stained with 
Wright-Giemsa (Figure 3.1.1).  Moreover, the phenotypes of these BM-DC, as 
shown in Figure 3.1.2, were comparable to that published for mature DC [174].  
 75
  
Table 3.1.1  Surface phenotypes of BM cells cultured with GM-CSF and IL-4  
at various time points  
Surface markers d0 d5 d7 d10 
CD3 5.3 5.4 8.1 3.8 
CD4 3.4 5.3 4.5 4.9 
CD8α 8.8 3.2 4.6 4.3 
CD19 46.7 7.8 5.2 7.8 
CD11c 4.5 30.5 50.2 63.4 
CD80 31.6 54.5 60.9 73.3 
CD86 21.6 36.3 56 66.2 
Class I  57.8 63.8 80.5 79.4 
Class II  10.7 50.5 82.4 80.8. 
















Figure 3.1.1  Purified bone marrow derived-DC (BM-DC) were stained with 
Wright-Giemsa. Wright-Giemsa staining of  (A) harvested bone marrow cells (B) 






















Figure 3.1.2 Surface phenotypes of purified bone marrow derived-DC (BM-DC).  
DC cultured from bone marrow in the presence of GM-CSF and IL-4 were 
purified and stained with anti-CD11c, anti-CD80, anti-CD86 and anti-class II 
MHC antibodies and analyzed by FACS.   
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3.1.2  Muc-1 pulsed DC could act as APC to antigen-specific CTL 
To  determine  if  the  DC  generated could function as APC, muc-1 peptide 
having the sequence, PDTRPAPGSTAPPAHGVTSAPDTRPAPGST, was 
synthesized.  The flu peptide having the sequence IASNENMETMESSTLE was 
also synthesized and acted as a control peptide.  To generate muc-1-specific CTL, 
three immunization protocols, as described in Materials and Methods, were 
followed.  Two types of target cells were employed in assessing the CTL 
activities: blast cells pulsed with the muc-1 peptide and transfected muc-1+RMA 
lymphoma cells (RMA-muc-1).  To investigate the optimal muc-1 peptide 
concentration to induce maximal CTL responses, spleen cells from immunized 
mice were re-stimulated in vitro with various peptide concentrations.  As shown 
in Figure 3.1.3, the highest CTL responses were achieved with 10μg/ml muc-1 
peptide stimulation.  In contrast to mice immunized with the muc-1 peptide that 
generate high level of anti-muc-1 antibody (Figure 3.1.4), mice immunized with 
muc-1 pulsed BM-DC cells displayed high levels of primary and secondary muc-
1-specific CTL (Figure 3.1.5). 
 
The highest level of muc-1-specific CTL activities were detected in mice 
immunized twice with muc-1 pulsed BM-DC and followed by a secondary in 
vitro stimulation with the muc-1 peptide (Figure 3.1.5).  No anti-muc-1 CTL 
responses could be detected in mice immunized twice with the muc-1 peptide 
(Figure 3.1.5).  The generation of high muc-1-specific CTL activities was 
correlated with the high level of CTLp detected in mice immunized with muc-1-
pulsed BM-DC (Table 3.1.2).  As shown in Table 3.1.2, the average CTLp 
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frequency was 1/583121 for mice that were immunized with the muc-1 peptide 
alone.  The CTLp frequency was greatly enhanced in mice that were firstly 
immunized with muc-1 peptide and then with the muc-1 pulsed BM-DC (average 
CTLp of 1/47329).  Mice given two immunizations with muc-1 pulsed BM-DC 
gave the highest average CTLp frequency of 1/32122.  The generation of muc-1-
specific CTL activities was also correlated with the production of IL-2 and IFN-γ 
in culture supernatants of spleen cells from mice immunized with muc-1-pulsed 
BM-DC (Figure 3.1.6). In comparison, culture supernatants of spleen cells 
obtained from mice immunized twice with the muc-1 peptide demonstrated high 
level of IL-10 and relatively low level of IL-2 and IFN-γ (Figure  3.1.6). 
 
After confirming that muc-1-pulsed BM-DC could generate efficient muc-1-
specific CTL, we explore the possibility of inducing the expansion of DC in vivo 
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Figure 3.1.3  Effect of peptide concentration on CTL responses. Spleen cells from 
mice immunized with muc-1-pulsed DC were re-stimulated with various muc-1 
peptide concentrations in vitro.  Spleen cells were harvested at d6 and tested for 




































































































































Figure 3.1.4  Detection of anti-muc-1 antibodies.  Sera were collected from mice 
10d after immunization with (A) muc-1 and muc-1 pulsed BM-DC (muc-1/BM-
DC) (B) muc-1/BM-DC and muc-1/BM-DC and (C) muc-1 and muc-1.  
Antibodies were determined by ELISA assay using muc-1 coated dishes as 
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Figure 3.1.5  MUC-1 pulsed BM-DC were able to generate potent and specific 
anti-muc-1 CTL responses.  Groups of 3 mice each were immunized either with 
(i) muc-1, muc-1 (ii) muc-1, muc-1 pulsed BM-DC and (iii) muc-1 pulsed BM-
DC, muc-1 pulsed BM-DC.  The 1st and 2nd immunizations were 10d apart.  CTL 
responses were determined 10d after the 2nd immunization as described in 





Table 3.1.2  CTLpa obtained in mice following immunization either with the 
muc-1peptide alone and/or muc-1-pulsed BM-DC or hFlex-DC 
aMean CTLp of three independent  mice. (*)( **) or (*)(***)  p<0.05 by Student’s T test.  
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Figure 3.1.6  Production of cytokines.  Spleen cells were harvested from mice 
immunized either with (i) muc-1, muc-1 (ii) muc-1, muc-1 pulsed BM-DC and 
(iii) muc-1 pulsed BM-DC, muc-1 pulsed BM-DC. The harvested spleen cells 
were further stimulated in vitro with synthetic muc-1 peptide. The respective 
culture supernatant was collected for IL-2, IFN-γ and IL-10 assay. Mice given 




3.1.3  Induction of CD11c+ DC via in vivo immunization with 
pNGVL3-hFLex plasmid DNA  
To determine the optimal time to administer the muc-1 peptide in vivo to achieve 
maximum CTL responses, we have studied the effect of the pNGVL3-hFLex 
plasmid DNA on the expansion of DC in vivo.  The kinetics of the induction of 
DC expansion in vivo were quantitated using FACS to determine the percentages 
of DC in the spleen, lymph nodes, thymus, blood and the peritoneal cavity of 
immunized mice at different time points following gene delivery by the 
hydrodynamic-based method.  As previously reported, following gene delivery of 
the pNGVL3-hFLex plasmid DNA, a peak serum level of 50-70 µg/ml Flt-3L 
was detected 24 hr after injection [179]. Flt-3L level was progressively decreased 
and maintained above or around 1µg/ml until d6 [179].  There was no noticeable 
toxicity resulting of the high level of Flt-3L in mouse serum.  A single injection 
of the pNGVL3-hFLex plasmid DNA could lead to 20%-30% of detectable 
CD11c+ DC in various lymphoid and non-lymphoid organs between d7 and d10 
following immunization.  However, there is a steady decrease in CD11c+ DC at 
d10 following immunization and the number of CD11c+ DC returned to the basal 
level by d20 (Figure 3.1.7).  No corresponding expansion of T cells could be 
detected.  The expansion of DC in vivo resulted in multiple organomegaly 
including that of the spleen and lymph nodes of the immunized mice.  The 
number of DC started to reduce from d12 onwards and by d20 it reached a level 
comparable to that of the unimmunized mice (Figure 3.1.7).  This may suggest 
the presence of a negative feedback regulatory mechanism in operation.  A 
second injection of the pNGVL3-hFLex plasmid DNA could again lead to the 
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expansion of DC, thus indicating that no tolerance mechanism is induced (Figure  
3.1.7).  The percentages of DC attained were comparable to that of the first 
injection (Figure 3.1.7).  The parental plasmid pNGVL3 has no effect on DC 
















































Figure 3.1.7  Kinetics of induction of DC via in vivo immunization with 
pNGVL3-hFLex plasmid DNA.  pNGVL3-hFLex plasmid DNA was injected 
into mice on d0 and d20.  Spleen cells were collected at different time points after 
DNA injection and CD11c+ cells were quantitated by FACS as described in 
Materials and methods.     
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3.1.4  Cell surface phenotypes of bone marrow-derived DC (BM-DC) 
and splenic DC induced by the pNGVL3-hFLex plasmid DNA (hFlex-DC) 
were identical 
After establishing the optimal kinetics for the induction of DC in vivo via 
injection of the pNGVL3-hFLex plasmid DNA, the phenotypes of the splenic 
hFlex-DC and BM-DC were studied.  Splenic hFlex-DC were isolated from the 
spleen of mice at 7d and 10d following the immunization with pNGVL3-hFLex 
plasmid DNA.  Both BM-DC and hFlex-DC exhibited high level of the co-
stimulatory molecules CD80 and CD86 (Figure 3.1.8).  However, injection of the 
pNGVL3-hFLex plasmid DNA resulted in the generation of lymphoid-derived 
DC (CD8α+) as well as the myeloid-derived DC (Figure 3.1.8 and Table 3.1.3).  
Table 3.1.3 summarized the characteristics of BM-DC and hFlex-DC collected at 
d7 and d10. 
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Figure 3.1.8  Comparison of the cell surface phenotypes of purified (A) bone 
marrow derived DC (BM-DC) and  (B) splenic DC induced by the pNGVL3-
hFLex plasmid DNA (hFlex-DC).  The DC were analyzed with anti-CD11c, anti-
CD80, anti-CD86 and anti-CD8α antibodies and quantified by FACS.  
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Table 3.1.3  Comparison of the characteristics of BM-DC and  hFlex-DC 
 
Characteristics  BM-DC* hFlex-DC** 
 
d7 d10 d7 d10 
 
 
























CD11c/CD86 cells 67.6% 75.6% 68.8% 73.2% 
CD11c/CD8 cells None None 25.1% 23.8% 
Allostimulation Yes Yes Yes Yes 
Ag presentation  Yes Yes Yes Yes 
 
*In vitro cultured with GM-CSF and IL-4 





3.1.5  hFlex-DC are immune competent  
To study whether the hFlex-DC were functional and able to act as APC in vitro, 
CD11c+ DC were purified from splenocytes at d7 and d10 following the injection 
of pNGVL3-hFLex plasmid DNA.  Although the absolute level obtained was 
slightly lower than that with BM-DC, hFlex-DC were capable of inducing allo-T 
cell reactivities (Figure 3.1.9A), generating muc-1-specific CTL (Figure 3.1.9B), 
and stimulating the production of IFN-γ and IL-2 (Figure 3.1.9C&D).  Most 
importantly, CTLp determinations for mice immunized with muc-1 pulsed hFlex-
DC (average CTLp of 1/44637) were comparable to that obtained by 
immunization with muc-1 pulsed BM-DC (Table 3.1.2).  From these results, it 
appeared that the BM-DC might be more efficient in functioning as APC in vitro 
than hFlex-DC, the hFlex-DC are nevertheless immune competent and are able to 
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Figure 3.1.9  hFlex-DC are functionally competent.  (A) Alloreactivity. hFlex-DC 
were capable of inducing allo-T cells reactivities. Purified γ-irradiated BM-DC or 
splenic hFlex-DC were co-cultured with allo-T cells and the reactivities measured 
as described in Materials and methods. (B) MUC-1 specific CTL.  MUC-1 pulsed 
hFlex-DC were able to induce muc-1 specific CTL.  BM-DC or hFlex-DC 
purified after immunization with pNGVL3-hFLex plasmid DNA for 7d and 10d 
were pulsed with the muc-1 peptide in vitro and then inoculated into mice.  Ten 
days later, spleen cells were collected and tested for secondary CTL activities.  
(C) and (D)  Production of cytokines.  Spleen cells harvested after immunization 
with the muc-1 pulsed BM-DC, hFlex-DC or RPMI media were stimulated in 
vitro with muc-1 peptide and the respective culture supernatant on d3 or d6 was 

































3.1.6  hFlex-DC are capable of processing the muc-1 antigenic 
peptide in vivo to generate potent anti-muc-1 CTL responses  
After demonstrating that the hFlex-DC are immune competent and are able to 
present antigens in vitro, we then investigated if the hFlex-DC generated in vivo 
following the injection of pNGVL3-hFLex plasmid DNA could act directly as 
APC to present antigens in situ.  Different amounts of the muc-1 antigenic 
peptides were employed for the immunization and different routes of 
administration of the muc-1 peptides were examined.   
 
Seven days following the injection of the pNGVL3-hFLex plasmid DNA, 60μg 
of the muc-1 peptide was injected directly into the spleens of mice (intra-splenic 
injection).  After 10 additional days, the immunized mice were sacrificed and the 
spleen cells harvested for CTL assays.  Significant muc-1-specific proliferative 
responses (Figure 3.1.10A) and anti-muc-1-specific secondary CTL responses 
(Figure  3.1.10B) could be demonstrated in mice primed with the pNGVL3-
hFLex plasmid DNA but not with the control parental vector pNGVL3 (Figure  
3.1.10).  No anti-muc-1 antibody could be detected in this group of immunized 
mice.  These results suggest that the in vivo expansion of DC following injection 
of the pNGVL3-hFLex plasmid DNA into the spleens of the recipient mice 
mainly activated the cellular pathway of the immune system. 
 
When 60μg of the muc-1 peptides were given via either intraperitoneally or 
intravenously following the injection of pNGVL3-hFLex plasmid DNA, no muc-
1-specific CTL response could be generated (Figure 3.1.10B).  However, when 
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300μg of the muc-1 peptide were given intravenously following injection of the 
pNGVL3-hFLex plasmid DNA, significant muc-1-specific secondary CTL 
responses could be detected (Figure 3.1.10B).  Following this immunization 
protocol with high concentration of the muc-1 peptide, the production of anti-
muc-1-specific antibodies in the recipient mice could also be demonstrated 
(Figure  3.1.11).  The summary of the various immune responses elicited 
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Figure 3.1.10  Generation of muc-1 specific immune responses via in vivo 
stimulation of DC with pNGVL3-hFLex plasmid DNA and muc-1 peptide.  Mice 
were first immunized with either pNGVL3 or pNGVL3-hFLex plasmid DNA and 
followed by a secondary immunization 7d later either with (i) 60μg muc-1, i.p. 
(ii) 60μg muc-1, intra-splenic (iii) 60μg muc-1, i.v. or (iv) 300μg muc-1, i.v.   
Spleen cells were harvested after 10d and cultured in vitro with muc-1 peptide 
employed for (A) Proliferative response (B) Secondary CTL assays with either 
RMA-muc-1 target cells (□ and ■) or RMA target cells (▧ and ▦) as described 


















































































































































































Figure  3.1.11  Induction of muc-1 specific antibody response via in vivo priming 
with pNGVL3-hFLex plasmid DNA and muc-1 peptide.  Mice were immunized 
with pNGVL3-hFLex 7d prior to stimulation with (A) 60μg muc-1, i.p. (B) 60μg 
muc-1, intra-splenic (C) 60μg muc-1, i.v.  (D) 300μg muc-1, i.v.  (E) Normal 
mouse sera were served as negative control. Antibody responses were determined 








































































3.1.7  Tumor-specific immune response induced by in vivo 
stimulation with pNGVL3-hFLex plasmid DNA and muc-1 peptide 
The ability of mice immunized with pNGVL3-hFLex plasmid DNA and muc-1 
peptide to induce effector CTL in vitro suggested that this immunization may 
also provide anti-tumor protection in vivo.  This was tested in a pre-treatment 
model whereby mice were first immunized with pNGVL3-hFLex plasmid DNA 
and muc-1 peptide and challenged 10 days later with a lethal s.c. injection of 
5x105 RMA-muc-1 or RMA tumor cells.  Mice pre-immunized with pNGVL3-
hFLex plasmid DNA and muc-1 peptide showed a delayed in tumor progression 
kinetics as compared to animals in negative control groups that were pre-treated 
with pNGVL3-hFLex plasmid DNA alone or muc-1 peptide alone in mice 
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Figure  3.1.12   Tumor-specific immune response induced by in vivo stimulation 
with  pNGVL3-hFLex plasmid DNA and muc-1 peptide.   Mice pre-treated with 
either pNGVL3-hFLex plasmid DNA alone, muc-1 peptide alone or pNGVL3-
hFLex plasmid DNA and muc-1 peptide as indicated were challenged with (A) 
RMA-muc-1 tumor cells (B) the parental untransfected RMA tumor cells.  The 
growth of tumors of each of the individual mouse in the different priming groups 
were monitored.   At each time point, the size of the tumor for the five mice 
within a group were taken together and compared statistically with the other 







3.2  Expansion and recruitment of DC in situ potentiate the 
immunogenicity of DNA vaccine encoding the antigenic epitope fused to 
human Flt-3L  
3.2.1  Generation and in vitro expression of pNGVL3-hFLex-muc-1 
DNA construct 
A DNA construct was generated encoding the extracellular domain of human Flt-
3 ligand (FL) ligated in frame to the tumor epitope muc-1, under the control of 
the CMV promoter (Figure 3.2.1), so as to express a fusion protein which 
exhibits dual functionality, cognizant of its respective components. The Flt-3 
ligand is a known potent inducer of DC expansion in vivo, and it is postulated 
that the secreted chimeric protein will enable a simultaneous targeting of the 
muc-1 epitope to the DC population, efficiently generating muc-1 loaded DC. 
Controls containing FL only or muc-1 only or empty vector were used as controls 
in this study (Figure  3.2.1). 
 
To confirm that the fusion protein can be expressed, we transfected A549 cells 
with pNGVL3-hFLex-muc-1, and stained with antibodies against FL (red) and 
muc-1 (green). The construct transfected efficiently (Figure 3.2.2), and as shown 
in Figure 3.2.2A, both FL and muc-1 proteins co-express at high levels in the 
cytoplasm. The levels of FL and muc-1 expression were then examined by 
Western blot analysis of total cell lysate from transfected A549 cells. Expression 
was detected with either a polyclonal antibody against FL (Figure 3.2.2B) or a 
monoclonal against muc-1 (Figure 3.2.2B).  Consistent with the 
immunofluorescence data, FL and muc-1 proteins are highly expressed in A549 
 101
cells transfected with pNGVL3-hFLex-muc-1. As expected the fusion protein 
resolves at a higher molecular weight corresponding to the combined sizes of FL 
and muc-1. Therefore we have established that the pNGVL3-hFLex-muc-1 
construct is able to efficiently express both components as a fusion protein. 
 
To confirm that the control constructs are able to express viable product, we 
transfected A549 cells with pNGVL3-muc-1.  MUC-1 expression was detected 
by confocal microscopy (Figure 3.2.2C).  pNGVL3-hFLex expression has 







FL pNGVL3-hFLexCMV Poly A
pNGVL3-hFLex-muc-1 FL Poly ACMV muc-1
muc-1 pNGVL3-muc-1CMV Poly A
 
 
Figure 3.2.1  Schematic representation of pNGVL3-hFLex, pNGVL3-hFLex-
muc-1 and pNGVL3-muc-1 DNA vaccines.  FL represents the extracellular 
domain of human Flt-3 ligand. 
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Figure 3.2.2   In vitro expression of pNGVL3-hFLex-muc-1 DNA vaccine.  A549 
cells were transfected with pNGVL3-hFLex-muc-1 plasmid DNA and stained 
with anti-muc-1 and anti-FL antibodies. (A) Immunofluorescence staining 
showed that both muc-1 (green) and FL (red) co-expressed in cytoplasm (yellow) 
Original magnification (i) 100x and (ii) 400x.  (B) Total cell lysate (50 μg 
protein) from transfected cells were loaded per lane, resolved by SDS-PAGE and 
immunoblotted.  The blot was probed with (i) anti-FL antibody and (ii) anti-muc-
1 antibody to detect the presence of fusion protein (C) Viability of control 
plasmid pNGVL3-muc-1 was confirmed by immunofluorescence staining against 
muc-1 epitope. Original magnification (i) 100x and (ii) 400x. 
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3.2.2  Hydrodynamic-based intravenous immunization of pNGVL3-
hFLex-muc-1 induces expansion of CD11c+ DC in vivo 1
Section 3.1 showed that using pNGVL3-hFLex, the hydrodynamic-based 
intravenous (i.v.) route of immunization induces the expansion of DC, which 
with subsequent intravenous presentation of tumor antigen peptide, resulted in a 
marked anti-tumor response.  Therefore we utilized the same route of 
immunization for the pNGVL3-hFLex-muc-1 genetic vaccine, using C57BL/6 
mice.  The fusion protein secreted into bloodstream would mimic the intravenous 
delivery of hFlt-3L and muc-1 peptide as described in section 3.1.  The expanded 
DC, induced by the Flt-3L component, would then be able to take up the muc-1 
antigen.  The amount of fusion protein secreted in blood sera was measured by 
ELISA, using an antibody against FL.  Different DNA concentrations, 10μg and 
20μg, were used to determine the optimal protein expression. There is no 
significant difference in protein expression levels between either DNA 
concentration used, and the levels of FL protein detected in mice injected with 
pNGVL3-hFLex-muc-1 is comparable to control mice injected with pNGVL3-
hFLex (Figure 3.2.3). This is consistent with earlier study that for hydrodynamic-
based intravenous injection, DNA saturation with maximal gene expression 
occurs at 5-10μg. The expression of fusion protein peaks at day 1 to day 2, with a 
concentration of 50-70ug/ml, which progressively decreases over time.  Though 




The Flt-3 ligand is a potent inducer of DC expansion [182-183]. Mice were 
inoculated with pNGVL3-hFLex-muc-1, pNGVL3-hFLex or empty vector by 
intravenous injection and splenocytes analyzed at various time points to 
determine the changes in DC population. Inoculation with either FL-derived 
plasmid DNA resulted in increased cellularity of the spleen (Table 3.2.1).  In 
Table 3.2.1, we show the changes in different splenic lymphocyte populations. 
Total T cell numbers (CD3+CD8+ and CD3+CD4+) remained constant after DNA 
immunization. There is a significant increase in CD11c+ cells, suggesting that the 
increased splenic cellularity is primarily due to DC expansion, and different DC 
subsets are shown to be upregulated, indicating a general expansion of DC types. 
There is also an increase in CD19+ B cells in the immunized mice, which 
correlates with previous reports that Flt-3 ligand also induces expansion of B 
cells [116].  The relative proportion of CD11c+/ClassII+ splenic cells in 
pNGVL3-hFLex and pNGVL3-hFLex-muc-1 immunized mice is virtually 
identical (Figure 3.2.4).  We then analyzed the kinetics of DC induction after 
immunization by determining the percentage of CD11c+/ClassII+ cells in the 
spleen over a time course.  As seen in Figure 3.2.5, from day 4 to day 6, there 
was a 20% increase in CD11c+/ClassII+ DC in mice immunized with either 
pNGVL3-hFLex-muc-1 or pNGVL3-hFLex, which was sustained to day 10 and 
then decreased gradually.  Addition of the muc-1 peptide epitope to the DNA 




In addition to the spleen, we demonstrated that Flt-3 ligand is able to induce 
CD11c+/ ClassII+ DC expansion in other lymphoid and non-lymphoid organs, 
which are traditional sites of DC activity (Figure 3.2.6).  The DC population 
peaks on the same day in all the organs examined, suggesting a systemic effect by 






















Figure 3.2.3  Dose response of pNGVL3-hFLex-muc-1 DNA vaccine.  Following 
hydrodynamic-based intravenous tail vein administration of 10 μg or 20 μg of 
pNGVL3-hFLex-muc-1 DNA vaccine, mouse sera was collected over a time 
course and expression of fusion protein was quantified by anti-FL ELISA kit.  
The expression level was compared with pNGVL3-hFLex plasmid DNA (10μg) 
as previously described in section 3.1. 
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Figure 3.2.4   Comparison of cell surface phenotypes of splenic DC induced 
by pNGVL3-hFLex and pNGVL3-hFLex-muc-1plasmid DNA. The spleen 
cells were harvested from (i) pNGVL3, (ii) pNGVL3-hFLex and (iii) 
pNGVL3-hFLex-muc-1 inoculated mice and stained with anti-CD11c and 
anti-class II MHC antibodies.  Subpopulations were gated and their 
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Figure 3.2.5  Kinetics of pNGVL3-hFLex-muc-1 induced DC expansion. 
Spleen cells were harvested from mice inoculated with 10μg of pNGVL3, 
pNGVL3-hFLex and pNGVL3-hFLex-muc-1 plasmid DNA over a time 
course.  Percentage of CD11c+ and class II+ cells was determined by FACS.  
Percentage of CD11c+/class II+ DC induced by 10 μg or 20 μg pNGVL3-




























Figure 3.2.6  pNGVL3-hFLex-muc-1 induced DC expansion in various 
organs.  Following delivery of pNGVL3-hFLex-muc-1 plasmid DNA, cells at 
various organs were collected and stained with anti-CD11c and anti-class II 
MHC antibodies. 
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3.2.3  DC generated by intravenous immunization are immune 
competent but fail to induce a tumor response. 
Having demonstrated that the chimeric DNA vaccine pNGVL3-hFLex-muc-1 is 
able to expand DC in vivo, we then investigated whether this induced population 
is able to act as APC in situ, and present antigen introduced via genetic 
immunization. Mice were first inoculated with pNGVL3-hFLex to generate an 
initial expansion of the DC population. This was done as protein expression from 
plasmid DNA in blood sera decreases to 1.5% (Figure 3.2.3) by day 7, which is 
the length of time required to obtain the peak DC expansion. At every 10 day 
interval, we administered a second and third immunization with pNGVL3-
hFLex-muc-1 via intravenous injection. 10 days post third immunization, the 
splenocytes were harvested, re-stimulated with muc-1 peptide in vitro, and 
assayed for anti-muc-1 specific secondary CTL activity using RMA-muc-1 tumor 
cells as target. As shown in Figure 3.2.7A, there is significant CTL activity 
exhibited by splenocytes from mice primed with pNGVL3-hFLex-muc-1. IFN-γ 
production is correlated with a Th1 response, which drives the propagation of 
effector CTL.  We show here that likewise, IFN-γ was detected only in the 
culture supernatant derived from pNGVL3-hFLex-muc-1 mice (Figure 3.2.7B), 
correlating with CTL activity.  In addition, anti-muc-1 antibodies were also 
detected in mice immunized with pNGVL3-hFLex-muc-1 (Figure 3.2.7C). 
 
In comparison to our previous study using a DNA and peptide combined 
vaccination (section 3.1), the pNGVL3-hFLex-muc-1 genetic vaccine is similarly 
able to generate antigen-loaded DC that are able to prime a CTL response. 
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Therefore we speculate that this DNA vaccine may also provide anti-tumor 
protection in vivo. 
 
This was investigated using an experimental tumor model, whereby mice were 
initially inoculated with pNGVL3-hFLex to augment the DC population and 
subsequently immunized with pNGVL3-hFLex-muc-1 by intravenous injection. 
10 days following the last immunization, the mice were challenged with a lethal 
dose of 5x105 RMA-muc-1 cells, injected subcutaneously (Figure 3.2.7D). 
However there was no detectable protection against the aggressive proliferation 
of the RMA-muc-1 tumor cells. This is in marked contrast to our previous report 
whereby muc-1 peptide pulsed pNGVL3-hFLex induced DC could induce a 
significant anti-tumor response. Though we are uncertain as to the underlying 
mechanism responsible for this difference, it has been reported that the route of 
immunization is critical in establishing the appropriate immune response. It was 
shown that DNA immunization via intramuscular (i.m.) route elicits a sustained 
CTL and antibody response [184] and in particular, intramuscular inoculation 















































































































Figure 3.2.7  Hydrodynamic-based intravenous ( i.v.) tail vein administration of 
pNGVL3-hFLex-muc-1 DNA vaccine induces antigen specific CTL responses 
but fails to confer tumor protection.  (A) Spleen cells from immunized mice were 
re-stimulated with 10μg/ml muc-1 peptide and tested for their ability to kill 
RMA-muc-1 target cells.  (B) Spleen cells were re-stimulated with muc-1 peptide 
or NP-Flu peptide as control peptide. At d3, culture S/N was collected and tested 
for the presence of IFN-γ.  (C) Sera from mice immunized with pNGVL3-hFLex-
muc-1 DNA vaccine was collected and assayed for muc-1 specific antibody 
response.  (D) Mice (n=10) were challenged subcutaneously with RMA-muc-1 
tumor cells at d10 from the last immunization with pNGVL3-hFLex or pNGVL3-
hFLex-muc-1 DNA vaccines. The tumor size of each of the individual mouse in 
the different priming groups were monitored.  
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3.2.4  Intramuscular immunization of pNGVL3-hFLex-muc-1 
induces antigen specific CTL response and results in anti-tumor protection. 
To investigate whether the intramuscular route of immunization will be more 
efficient in generating an anti-tumor response, pNGVL3-hFLex-muc-1 was 
inoculated via intramuscular direct needle injection into C57BL/6 mice, and the 
level of protein expression in vivo assayed. No fusion protein could be detected in 
the blood sera after immunization with 20μg of plasmid DNA. It is most likely 
that the amount of protein secreted is less than 10 pg/ml, below the threshold of 
detection for ELISA. However, transgenic protein could be detected in the 
muscle tissue around the site of injection at day 1 post-immunization, 0.2 pg 
fusion protein per mg muscle tissue (Figure 3.2.8A). This suggests that plasmid 
DNA, when inoculated via intramuscular injection, tends to be expressed locally. 
Correlating with the lack of transgenic Flt-3 ligand in the sera, there was no 
detectable expansion of DC population in the spleen. 
 
In spite of poor response to the Flt-3 ligand component, we harvested splenocytes 
from immunized mice and assayed for muc-1 specific CTL activity. Injection of 
DNA into muscle has previously been reported to result in transient infiltration 
by immune cells, and therefore though muscle does not contain significant 
numbers of APC, additional cells are recruited on DNA injection and obtain 
antigen from transfected muscle cells [186-187].  Mice were immunized with 
pNGVL3-hFLex-muc-1 and as shown in Figure 3.2.8B, there is significant anti-
muc-1 specific CTL activity exhibited by isolated splenocytes stimulated in vitro 
with muc-1 peptide.  Mice were also intravenously inoculated with pNGVL3-
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hFLex to stimulate systemic DC expansion prior to intramuscular immunization 
with pNGVL3-hFLex-muc-1 chimeric DNA vaccine to bolster the immune 
response. The CTLp frequency with or without prior DC expansion was 
comparable (Table 3.2.2). This implies that pNGVL3-hFLex-muc-1 introduced 
intramuscularly does not require prior DC augmentation to generate a potent CTL 
response.  Intramuscular vaccination of pNGVL3-muc-1 was not able to generate 
a significant specific immune response.  Mice immunized with pNGVL3-hFLex-
muc-1 DNA vaccine showed higher CTLp frequency (average CTLp of 1/60100) 
as compared to pNGVL3-muc-1 inoculated mice (average CTLp of 1/447500) 
(Table 3.2.2). This suggests that pNGVL3-hFLex-muc-1 DNA vaccine is more 
superior in enhancing T cell immunity. The presence of active CTL was further 
supported by the detection of IFN-γ in culture supernatant (Figure 3.2.8C). 
Comparable levels of IFN-γ were produced in corresponding samples that 
exhibited CTL activity.  However, there was no significant antibody response in 
mice immunized with pNGVL3-hFLex-muc-1. 
 
The significant effector CTL activity suggested a promising anti-tumor 
protection. Therefore we challenged immunized mice with RMA-muc-1, as 
described previously. The following immunization regimes were used; 3X 
intramuscular immunization with pNGVL3-hFLex-muc-1 alone; initial DC 
augmentation with pNGVL3-hFLex followed by 3X intramuscular inoculation 
with pNGVL3-hFLex-muc-1; control immunizations using pNGVL3-hFLex or 
pNGVL3-muc-1. Figure 3.2.9A presents tumor size following the 3X 
immunization regimes and demonstrate conclusively tumor protection in mice 
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inoculated with pNGVL3-hFLex-muc-1. 1x and 2x immunization with pNGVL3-
hFLex-muc-1 did not confer tumor protection ability.  Figure 3.2.9B 
demonstrated that the anti-tumor response was muc-1 specific as tumor size of 
parental RMA tumor cells progressed aggressively. Advance DC stimulation 
prior to pNGVL3-hFLex-muc-1 vaccination did not appear to provide an 
advantage for tumor protection (Figure 3.2.10A).  In comparison, inoculation of 
pNGVL-muc-1, with or without DC augmentation, did not confer any protection 
(Figure 3.2.10B).  This suggests that in our system, Flt-3L possibly acts as an 
adjuvant to enable muc-1 processing and presentation by APC to generate an 
efficient immune response, and that the intramuscular route of immunization is 
the preferential route when presenting a genetic epitope.   
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Figure 3.2.8  Intramuscular administration of  pNGVL3-hFLex-muc-1 DNA 
vaccine generates muc-1 specific cellular responses. (A) Muscle tissues adjacent 
to the immunization site were harvested at various time points and expression of 
fusion protein was assayed by ELISA, using an antibody against Flt-3L. Spleen 
cells from the immunized mice were harvested and re-stimulated with 10μg/ml 
muc-1 peptide or NP-Flu peptide as control in vitro (B) At d6 post-stimulation, 
CTL activities were tested against RMA-muc-1 target cells. (C)  At d3 post-





Table 3.2.2  CTLp obtained in mice following immunization either with 
pNGVL3-hFLex, pNGVL3-muc-1 or  pNGVL3-hFLex-muc-1 plasmid DNA 
 
Immunization CTLp frequency
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Figure 3.2.9  Intramuscular immunization with pNGVL3-hFLex-muc-1 DNA 
vaccine induces a potent anti-tumor response. Mice were immunized 3x with 
pNGVL3-hFLex-muc-1 and pNGVL3-muc-1 DNA vaccines.  At d3 from the 
third immunization, mice were challenged subcutaneously (s.c.) with 5x105 (A) 
RMA-muc-1 (n=13) or (B) RMA parental cells (n=7).  The tumor growth from 
each experimental group was monitored.  At each time point, the tumor size of 
each mouse from a given group were collated and compared statistically with 
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Figure 3.2.10  Advance systemic DC expansion prior to immunization with DNA 
vaccines does not elicit a more potent anti-tumor response.  Mice pre-inoculated 
with pNGVL3-hFLex (delivered intravenously) to induce systemic expansion of 
DC population prior to intramuscular immunization with (A) pNGVL3-hFLex-
muc-1 (n=13) or (B) pNGVL3-muc-1 (n=13), were compared with mice that only 
received the intramuscular immunization with DNA vaccines.  Tumor size of 
individual mouse from each group was monitored.  * and ** p>0.05 by unpaired 
T test  at each time point.  
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3.2.5   Recruitment of DC to intramuscular immunization sites by 
pNGVL3-hFLex-muc-1 DNA vaccine 
To investigate the adjuvant activity of Flt-3L in enhancing the pNGVL3-hFLex-
muc-1 DNA vaccine, muscle tissues adjacent to the DNA vaccine inoculated sites 
were harvested and sectioned.  Figure 3.2.11A showed the hematoxylin staining 
of muscle sections from the pNGVL3-muc-1 and pNGVL3-hFLex-muc-1 
plasmid DNA inoculated mice.  The pNGVL3-hFLex-muc-1 plasmid DNA 
inoculated muscle sections showed massive mononuclear cells infiltration. In 
contrast, muscle sections inoculated with pNGVL3-muc-1 exhibited a smaller 
magnitude of cell infiltration.  Immunohistochemical staining (IHC) was 
conducted to identify specific cell types recruited to the immunization sites.  
CD11c+ DC were identified within the mononuclear cell infiltrate from muscle 
sections inoculated with pNGVL3-hFLex-muc-1 plasmid DNA (Figure 3.2.11B).  
However, there was no significant level of CD3+ T cells and CD8α+ cells 
detected within the mononuclear cell infiltrate.  Therefore, the ability of Flt-3L in 
enhancing the potency of pNGVL3-hFLex-muc-1 DNA vaccines could have 
attributed to its ability to increase recruitment of CD11c/CD8α- DC to the 
immunization sites.  The recruited DC are postulated to cross-present the secreted 
FL-muc-1 fusion protein to T cells.  Nevertheless, we cannot rule out the possible 
involvement of other APC such as macrophages within the cell infiltrate in 
eliciting T cell immunity. Interestingly, advance DC expansion prior to DNA 
vaccines inoculation did not seem to further enhance the specific immune 
response, indicating that local recruitment (in situ) of DC, rather than systemic 
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expansion of DC, is crucial in determining the efficacy of intramuscular 




















Figure 3.2.11  Immunohistochemical staining (IHC) of muscle sections from 
pNGVL3-hFLex-muc-1 and pNGVL3-muc-1 vaccinated mice.  Muscle tissues 
were harvested and sectioned at d3 after 2nd immunization. (A) Muscle sections 
were stained with Harris Hematoxylin. Muscle sections immunized with 
pNGVL3-hFLex-muc-1 DNA vaccine showed massive mononuclear cell 
infiltrations.(100x magnification)  (B) Muscle sections were stained with anti-
mouse CD11c, CD3 and CD8α antibodies. Significant level of CD11c+ DC, as 
indicated by brown color stain, were detected within the mononuclear cell 
infiltrates of pNGVL3-hFLex-muc-1 vaccinated mice.  CD3+ T cells and CD8α+ 








4.1  Generation of potent and specific cellular immune responses 
via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA 
and immunogenic peptides 
The ability to generate a potent antigen-specific cellular immune response 
depends on many factors including the nature of the antigen and the route of 
immunization.  Peptide vaccination is the most widely employed strategy and 
was first clinical tested in cancer immunotherapy.  Among the peptide 
immunotherapies, melanoma peptides were the first to be tested in clinical trials 
of metastatic melanoma patients.  In the clinical trial, 42% of patients receiving a 
modified gp100 peptide (gp100-209.2M) and a high systemic dose of IL-2 
showed a clinical response.  Patients who received the peptide alone showed no 
response [188].  In general, peptide is a weak immunogen which requires 
adjuvant activity.  Professional DC are often regarded as ‘natural adjuvant’ with 
the exquisite capability to stimulate naive T cells.   It has been long recognized 
that two signals are required for the initial activation of naive T cells.   The 
activation of naive T cells requires an antigen to be presented by an MHC 
molecule (signal 1) together with the costimulatory molecules CD80 and CD86 
(signal 2).  These two signals are provided by the most efficient professional 
APC-dendritic cells (DC). Conversely, if only signal 1 is presented, which is the 
case for the majority of tumor cells, an immune response will not be initiated 
because signal 2 is lacking, which helps maintain peripheral tolerance or 
ignorance of tumor  antigens. 
 
 127
DC have emerged as the most powerful APC to stimulate naive T cells because 
they express high levels of the MHC molecules and immune co-stimulatory 
accessory molecules as well as the secretion of many potent T-cell-activating 
cytokines that are critical for the generation of an effective immune response.  
DC are specializing in capturing and presenting antigens to stimulate T-cell 
dependent immunity.  In addition, DC have a high motility which allows them to 
traffic from the site of antigen to the T-cell areas of lymph nodes.  Therefore, DC-
based immunotherapy remains as an attractive strategy to improve vaccine 
efficacy.   
 
The identification of TAA recognized by CTL has improved the prospect for 
cancer immunotherapy.  One family of TAA that can induce a specific immune 
response is the mucin molecules.  Mucin molecules, such as muc-1, are large 
transmembrane glycoproteins that have been recognized as potential targets for 
immunotherapy in human adenocarcinomas.  Several lines of evidence have 
demonstrated that muc-1 can act as an immuno-dominant epitope to generate T- 
and B-cell immunity [189].  In cancers of the gastrointestinal tract, ovary, breast, 
pancreas, kidney, and lung, muc-1 was found to be hypo-glycosylated and 
showed a 10- to 40-fold increase in expression [190]. The under-glycosylation of 
muc-1 exposes a highly immunogenic peptide epitope within a variable number 
of tandem repeats (VNTR).  
 
In this report, we have designed a 30-mer synthetic muc-1 peptide containing the 
amino acid sequence of the tandem repeats and were able to demonstrate initially 
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that BM-DC derived in vitro could elicit muc-1 specific CTL when pulsed with 
muc-1 peptide (Figure 3.1.5).  This is likely to be a Th1 immune response as high 
levels of IL-2, IFN-γ and low levels of IL-10 were detected (Figure 3.1.6).  This 
is in marked contrast to the generation of muc-1 antibody response when the 
muc-1 peptide is employed directly for immunization (Figure 3.1.4).  
Accumulating evidence also suggests that the types of cytokines secreted during 
the early stages of primary responses are crucial factors that determine the 
outcome of the immune responses and the types of T cells generated [191]. DC 
are able to produce and secrete IL-12, a cytokine that can induce naive CD4+ Th0 
cells into IFN-γ-secreting Th1 lymphocytes [192].  The differentiation of Th0 to 
Th1 cells could explain the ability for mice to generate CTL responses following 
immunization with muc-1-pulsed DC.  Interestingly, the production of high titer 
of IL-10 in mice immunized with muc-1 peptide that could potentially induce 
Th2 cells [193] correlated with the production of antibody (Figure 3.1.4).  This 
agrees well with other reports [194-195] and suggests that there are only a low 
number of APC, including DC, that are available to trigger an efficient cellular 
response in vivo. 
 
Previously, it has been reported that the Flt-3L protein could induce the 
expansion of DC in vivo.  Therefore, the administration of 10μg/mouse/day of the 
hFlt-3L protein for 9d consecutively would result in 15-20% detectable DC in 
vivo [183].  In the present report, we have studied, in a murine model, the 
generation of potent peptide-specific CTL responses via a single genetic 
immunization with the pNGVL-3-hFLex plasmid DNA and the immunogenic 
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peptide muc-1.  Our approach is based on the assumption that the expansion of 
DC in situ will enhance APC and would subsequently increase the ability of the 
immunized host’s cellular immune responses to exogenous peptides.   The 
approach is based on another specialty of DC in antigen presentation.  DC has the 
unique capability to present exogenous antigen to MHC-class I pathway. In 
classical view, exogenous antigen are presented via MHC-class II whereas 
endogenous antigen are presented to MHC-class I pathway. The non-classical 
presentation of exogenous antigen is termed ‘cross-presentation’ or ‘cross-
priming’.  The exogenous pathway allows DC to present many forms of 
nonreplicating antigens on MHC class I and thereby to elicit CD8+ CTL.  Active 
infection and biosynthesis do not need to take place in the DC.   
 
The understanding of cross-presentation of exogenous soluble protein antigens 
are derived mostly from the studies employing OVA peptide. It has been 
demonstrated that a single inoculation of a high dose of OVA, without adjuvant, 
resulted in a significant level of CTL response [196]. The CTL responses can be 
enhanced in the presence of incomplete Freund’s adjuvant. However, the 
threshold antigenic concentration required for in vivo cross-presentation is not yet 
defined, perhaps, depending on the nature of antigens and the presence of 
adjuvant activity. Particulate antigens are presented more efficiently than that of 
soluble antigens [197]. Proteins internalized through macropinocytosis, 
phagocytosis and receptor-mediated endocytosis can be cross-presented to MHC-
class I pathway [198-199]. However, the mechanisms underlying the cross-
presentation are not well defined. The release of antigen from endosome to 
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cytosol might be a critical attribute in accessing to MHC-class I presentation 
pathway.    
 
Moreover, the ability to expand DC in situ circumvents many practical problems 
currently associated with the culturing of DC from their BM progenitors in vitro.  
The generation of BM-DC needs to employ many expensive cytokines.  
Moreover, the culturing of DC in vitro might encounter additional problems such 
as contamination and the possible changes in the physiological properties of DC.  
For example, GM-CSF is commonly employed for the culturing DC in vitro 
[174].  However, it was reported that GM-CSF-treated mice did not generate a 
significant increase in the number of DC in the lymphoid and non-lymphoid 
compartments [200]. This evidence suggest that perhaps other additional growth 
factors might also be important for the generation of DC in vivo and the DC 
obtained through culturing in vitro could potentially be somewhat different from 
that generated in vivo.  Therefore, the ability to expand DC in vivo following the 
injection of the pNGVL3-hFLex plasmid DNA as demonstrated in this report 
offers the additional advantages including the generation of potentially multiple 
DC subsets that might be of great importance in eliciting optimal antigen-specific 
responses [201].  This is especially important in light of the fact that although the 
exact lineage derivation of DC remains controversial, there is growing evidence 
to suggest that DC could be subdivided into myeloid-derived and lymphoid-
derived subsets [10].  Each subset might potentially play a different role in the 
regulation and generation of immune responses.  In addition, the in vivo 
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expansion of DC occurs in both lymphoid and non-lymphoid organs and thus 
would enhance the chances of allowing its interaction with T cells.  
 
Several attempts to employ the soluble form of the mucin molecules such as 
mucin glycoproteins, recombinant mucin molecules, or synthetic mucin peptides 
to generate cellular responses had failed.  The introduction of the muc-1 cDNA 
into DC or EBV-transformed B cells with various viral constructs [202-203] and 
the utilization of muc-1 fusion protein to induce specific muc-1 immune 
responses [167] have also been reported.  In these reports, only antibody response 
could be generated but not T cell response.  In addition, a phase I trial employing 
a muc-1 synthetic peptide vaccine of 105 amino acids failed to demonstrate an 
anti-tumor response [204].  The phase I clinical vaccine trial employing the muc-
1-mannan fusion protein generated strong antibody responses but poor cellular 
responses [168].  The ability to demonstrate the generation of muc-1-specific 
CTL with our approach is of great interest as this shows the potential of 
employing the VNTR region as immunogen to stimulate T- and B-cell cellular 
responses in humans.  The single injection of the pNGVL3-hFLex plasmid DNA 
to expand DC in vivo would greatly simplify the procedures of potential 
immunotherapeutic protocols. The CD11c+ DC when purified by MACS 
magnetic separation from the spleens of mice at d7 and d10 following 
immunization with the pNGVL3-hFLex plasmid DNA were fully functional and 
could act as APC. 
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In the present study, we could only detect the production of anti-muc-1 antibodies 
but not CTL response if mice were immunized only with the synthetic 30-mer 
muc-1 peptide (Figure 3.1.5).  However, when the same synthetic 30-mer muc-1 
peptide were presented in the context of BM-DC or hFlex-DC, potent anti-muc-1 
CTL responses could be detected (Figure 3.1.9).  Apparently, DC pulsed with 
peptides such as muc-1 were able to divert the outcome of the immune response 
from a humoral response to that of a potent cellular immune response.  Mice that 
were immunized with two doses of muc-1-pulsed DC had slightly higher CTLp 
frequency (1/32122) in comparison to mice that were firstly immunized with 
muc-1-pulsed DC and then received a second immunization with the muc-1 
peptide (1/47329).  Moreover, mice that were immunized with two doses of muc-
1-pulsed hFlex-DC gave a CTLp frequency of 1/44637.  All of these CTLp 
frequencies were much higher than that obtained for mice immunized twice with 
the muc-1 peptide (1/583121).  
 
Interestingly, it was observed that muc-1/hFlex-DC induced a relatively lower 
level of CTL responses, lower level of IFN-γ and IL-2 in comparison with that of 
muc-1/BM-DC.  The exact explanation for these quantitative differences in the 
level of responses is currently unknown.  The immunogenicity of DC would 
undoubtedly depend on many factors [205]. It has also been shown previously 
that the in vitro culture conditions employed to generate BM-DC could play a 
role in determining their subsequent immunogenicity in vivo [206].  
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The ability to generate immune competent DC in vivo via a single genetic 
immunization with the pNGVL3-hFLex plasmid DNA and to generate a 
subsequent potent peptide-specific CTL response when coupled with 
immunogenic peptides such as muc-1, will undoubtedly allow the design of 
alternative approaches for the cellular immunotherapy of human cancers.   
 
However, when employed in human clinical study, several parameters need to be 
considered. Since the above strategy requires in vivo DC expansion, the 
functional competence of immune cells, in particular that of DC, in cancer 
patients requires careful examination.  Several studies have been conducted to 
expand DC from healthy human subjects. Administration of recombinant Flt-3L 
or G-CSF subcutaneously to healthy human volunteers increased the number of 
circulating CD11 +IL-3Rαlow DC and CD11 -IL-3Rαhigh DC precursors [207]. 
Importantly, the CD11c+ DC were efficient stimulators of T cells in vitro.  Flt-3L 
and G-CSF administration was well tolerated.  In addition, administration of Flt-
3L resulted in a dramatic increase of various DC subtypes.  The ability to expand 
a diverse repertoire of DC subsets may obviate many of the issues regarding 
which subtype is most appropriate for the generation of clinically effective 
immunity in vivo.  These encouraging results demonstrated that subcutaneous 
administration of Flt-3L may provide a mechanism for increasing the number and 
function of DC in cancer patients.  
 
However, in cancer patients, the composition of immune cells could be differing 
from healthy human subjects.  Their pathological states could affect DC biology 
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in at least two ways. First, composition of different DC subtypes might be 
skewed and secondly functionality of DC would be impaired.   
 
DC from cancer patients have been demonstrated impaired in function.  
Compared with those from healthy donors, DC cultured from the peripheral 
blood of esophageal cancer patients expressed lower CD80 and CD86 [208].  
Furthermore, the ability of DC in patients to induce T lymphocyte proliferation 
was significantly lower than that of the control group.  However, functional 
deficiency of DC is dependent on cancer type because DC from prostate cancer 
patients are capable of cross-presenting influenza antigen derived from 
internalized apoptotic prostate tumor cells [209]. In addition, autologous 
monocyte-derived DC from cervical cancer patients when pulsed with 
recombinant HPV E7 oncoprotein can induce T cell immunity in certain late-
stage cancer patients [210].   The impairment of function has been associated 
with dysfunctional maturation of DC.  When FACS analysis was done on whole 
blood of breast cancer patients (n=53) and healthy subjects (n=68), it was found 
that myeloid subpopulation, in particular, was markedly reduced in cancer 
patients [211].  Furthermore, they were impaired in the production of IL-12 
[211].  Interestingly, these alterations were reverted by surgical resection of the 
tumor, suggesting the presence of regulatory molecules in cancer patients.  It was 
found that spermine, an immunoactive soluble factor, has an inverse correlation 
with the percentage of DC expressing IL-12. Evidence was also obtained that in 
vitro exposure of monocyte-derived DC to spermine promoted their activation 
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and maturation, and therefore impaired their function [211]. This suggests that 
spermine could be a mediator of dysfunctional maturation of DC.   
 
It is worth noting that cancer types would affect the DC composition.  DC from 
patients with T lineage ALL (T-ALL) were quantitatively and functionally 
comparable to healthy donors, as demonstrated by secretion of interleukin (IL)-
12p70 and interferon-alpha [212].  However, in vitro, the circulating CD34(+) 
fraction of B-ALL cases did not generate either CD1a(+) myeloid DC or 
plasmacytoid DC, suggesting that DC development is probably affected in B-
ALL, but not in T-ALL [212].  This holds true for breast cancer and non-small 
cell lung cancer (NSCLC) [213].  The percentage of myeloid and lymphoid DC 
populations was significantly lower in patients with NSCLC than in the control 
group.  In patients with breast cancer, the number of lymphoid DC, however, was 
significantly higher than in NSCLC patients [213].   This suggests to us that 
changes in percentage of DC subtype in the peripheral blood from cancer patients 
maybe closely related with the type of tumor.   
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So far, there are limited reports on in vivo DC expansion by administration of Flt-
3L or other growth factors i.e. GM-CSF in cancer patients.  Freedman and 
colleagues [214] attempted to expand DC of patients with peritoneal 
carcinomatosis and mesotheliomas.  FL administration was done intraperitoneally 
or subcutaneously. The treatment resulted in the increase of monocytes, DC and 
platelets.  More importantly, DC obtained from the peripheral blood and 
peritoneal fluid could response to activation stimuli, suggesting its functional 
competency.  In another study, it was demonstrated that Flt3 ligand, although 
capable of inducing expansion of circulating myeloid and plasmacytoid DC in 
patients with metastatic renal cell carcinoma, lacks significant clinical activity 
[215].  Therefore, the competence of DC should be careful examined before 
realizing the system in cancer patients.   
 
4.2  Expansion and recruitment of DC in situ potentiate the 
immunogenicity of DNA vaccine encoding the antigenic epitope fused to 
human Flt-3L  
DNA vaccination is a contemporary vaccine strategy.  For the past few years, it 
has attracted great attention when Wolff et al [216] observed that mouse muscle 
cells express foreign antigens encoded by a naked plasmid DNA that was injected 
intramuscularly. Ulmer et al [217] made the first demonstration of the protective 
efficacy of a DNA vaccine encoding for influenza A nucleoprotein.  Subsequent 
studies further demonstrates that direct injection of naked plasmid DNA induces 
a strong, long-lived immune response to the encoded antigen [218], and such 
protocols have been successfully employed against infectious diseases induced by 
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agents such as viruses, bacteria and parasites [217,219].  In addition to the nature 
of the antigen, the DNA delivery method and route also influence the immune 
response generated. Though several methods have been developed to deliver 
DNA vaccines [218,220], intramuscular inoculation via direct needle injection of 
plasmid DNA has been shown to induce long lasting antigen specific humoral 
and cellular response [221-223].  Despite the protective effect of DNA 
immunization, the precise mechanism of action remains unraveled.  There are 
many unanswered questions such as which cell types are responsible for antigen 
presentation and the optimal route of DNA immunization.  
 
In section 3.1, we demonstrated that intravenous inoculation of pNGVL3-hFLex 
induced the expansion of DC in situ, and which on intravenous introduction of 
muc-1 peptide, generated muc-1 specific CTL response. In order to enable a more 
efficient approach, a DNA construct was generated encoding the extracellular 
domain of human Flt-3L ligated to the muc-1 epitope, so as to express a fusion 
protein which exhibits dual functionality, cognizant of its respective components.  
It is postulated that transfected cells will express and secrete the muc-1 fusion 
protein, thereby allowing uptake by expanded or recruited DC, which will then 
process and present the antigen to lymphocytes.  This type of immunization is 
termed genetic immunization/DNA immunization in which antigen is encoded by 
a plasmid DNA.  
 
Genetic immunization using naked DNA is an attractive approach to vaccinate 
against tumor-associated antigens in cancer immunotherapy. It offers several 
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advantages over peptide-based vaccination; 1) duration of expression of the 
peptide antigen in peptide pulsed DC is restricted by its half life; 2) antigen 
introduced as a transgene can be cross presented on MHC Class I and Class II to 
initiate both cellular and humoral immune responses; 3) plasmid DNA is 
relatively stable and easy to generate and cost effective compared to peptides; 4) 
DNA vaccine is feasible for manipulation.  One can modulate both the magnitude 
and orientation of a specific immune response by changing the method or 
location of immunization, altering the number of immunostimulatory sequences 
in the plasmid, altering the immunization regimen, or coadministering genes for 
cytokines or costimulatory molecules. 
 
By fusing the muc-1 antigen to a secretory DC-related protein, it is postulated 
that transfected cells will express and secrete the muc-1 fusion protein, thereby 
allowing captured by DC, which will then process and present the antigen to T 
lymphocytes in lymphoid organs.  In addition to presenting antigen in association 
with MHC Class II, DC have the unique ability to translocate exogenous antigen 
internalize by various pathways to MHC Class I presentation [223].  Another 
advantage of DNA vaccines is that transfected cells, whether immunologic or 
somatic, are able to express the protein encoded resulting in MHC Class I 
presentation. 
 
We demonstrate that despite linkage with muc-1 peptide, the efficacy of the hFlt-
3L component to expand DC is not impaired. Expansion of DC in vivo 
circumvents complex procedures required to isolate and culture DC progenitors 
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in vitro before re-introducing the cells back into the host.  Human Flt-3L has also 
been shown to expand multiple subsets of DC and in different organs, which is 
ideal for immunotherapeutic purposes to obtain an optimal response [183, 205].  
Our approach is based on the assumption that expansion of DC in situ will 
enhance antigen presentation and subsequently increase the ability of the 
immunized host’s immune system to respond to exogenous peptide. We showed 
that a single inoculation of hFlt-3L is able to expand DC populations in vivo by 
20% in 7 days (Figure 3.2.5). Subsequent intravenous inoculation with pNGVL3-
hFLex-muc-1 produced anti-muc-1 specific CTL, correlating with increase in 
IFN-γ production (Figure 3.2.7). This implies that genetic immunization of DNA 
encoded tumor antigen is able to generate a Th1 response, which is mediated by 
DC.  However, despite the induction of muc-1 specific immunoreactivity, there 
was no protection upon challenge with RMA-muc-1 tumor cells. It is unclear why 
that is so. One possibility is that the immune response generated was insufficient 
(average CTLp of 1/198500) to halt the aggressive proliferation of the tumor 
cells.  It is also likely the timing of the immunizations is critical and the protocol 
used may not be optimal.  The presence of anti-muc-1 specific antibodies might 
facilitate the clearance of the fusion protein by forming an antigen/antibody 
complex.  Though intravenous route of administration is conventional for peptide 
vaccines, it has been reported that naked DNA is more efficiently administered 
intramuscularly or intradermally [217,222].  The magnitude and duration of the 
immune response is dependent on the immunization route and cellular 
localization of the expressed protein [220-221], and it has been shown that the 
expression of a foreign protein in the muscle following direct in vivo gene 
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transfer results in the induction of potent cellular and humoral immune response 
[224].  Immunization via the intramuscular route recruits professional APC from 
the host bone marrow, and these APC take up the exogenous antigen and presents 
to lymphocytes to induce a cellular immune response [221,225]  
 
In this study, we report that mice immunized with pNGVL3-hFLex-muc-1 via 
intramuscular route produced high levels of muc-1 specific CTL and IFN-γ, and 
that this response is sufficient to confer protection against RMA-muc-1 induced 
tumors.  This protection occurs in spite of the lack of transgenic protein secreted 
into blood sera.  Within the muscle tissue, APC are sparse, and though they may 
be recruited to the injection site, it is unlikely sufficient numbers of APC will be 
transfected.  This might explain the lack of immunogenicity of pNGVL3-muc-1 
DNA vaccine.  It has been demonstrated that muscle cells take up the injected 
DNA and produce the protein product for a significant period of time [216]. 
Length of time of expression depends on cellular localization of the protein. 
Secreted proteins are expressed for a shorted period of time, approximately 20 
days [226].  However, there have been many reports that presentation of antigen 
by somatic cells, which lack co-stimulatory molecules, are more likely to induce 
tolerance [227]. A number of investigators have addressed this question by 
showing that the initiation of the immune response following DNA immunization 
into muscle is dependent on the recruitment of bone-marrow derived APC such 
as DC, which then traffic to draining lymph nodes with the processed antigen 
[223, 228-229].  In our study, immunization with pNGVL3-hFLex-muc-1 DNA 
vaccine, but not with pNGVL3-muc-1 DNA vaccine, induced massive infiltration 
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of CD11c+/CD8α- DC to the injection site.  The pNGVL3-hFLex-muc-1 DNA 
encodes for a secreted Flt-3L-muc-1 fusion protein.  The adjuvant activity of Flt-
3L within the fusion protein might have associated with its capability to recruit 
DC in situ.  In addition, it has been shown that the location of expressed antigens 
would affect the potency of DNA vaccine. It has been demonstrated that secreted 
protein was the most effective in stimulating both CTL and humoral responses, 
whereas cytoplasmic protein failed to induce any immune response [221,230]. 
Morel et al [230] demonstrated that intramuscular immunization with secreted 
OVA led to potent CTL while immunization with cytoplasmic OVA was 
ineffective.  Protein can be transferred from somatic cells to APC for presentation  
[229,231].  It is postulated that cytoplasmic antigen is not transferred to the BM 
derived APC/DC as efficiently as the secreted form and hence demonstrating an 
effective CTL response. This suggests a mechanism through which immunity was 




Figure 4.1  The roles of antigen presenting cells (APC) in the induction of 
immune responses via intrasmucular DNA immunization. 
APC 
MHC-restricted class I/II 
Plasmid DNA 
Muscle cells/ 
Somatic cells APC MHC-restricted class I/II Secreted 
“danger” 
MHC-restricted class I/II APCApoptotic cells 
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Despite the protective effect of DNA immunization, the exact mechanisms 
underlying the induction of immune responses are not fully understood. It is 
suggested that the induction of immunity via DNA immunization could occur in 
at least 2 ways (Figure 4.1): (1) APC/DC are directly transfected with plasmid 
DNA, leading to the generation of MHC-class I restricted immunity. However, 
this mechanism is restricted by the rarity of APC/DC within the muscle tissues.  
(2) Muscle cells or other somatic cells, instead of APC, are directly transfected 
with plasmid DNA. The induction of immunity via this mechanism depends on 
the location of expressed proteins. For cytoplasmic proteins, presentation of 
antigens by muscle cells which lack co-stimulatory molecules leading to immune 
tolerance instead of immune induction. However, if the transfected muscle 
cells/somatic cells are undergone apoptosis, the transfected apoptotic cells are 
phagocytosed by DC. The antigens will be cross-presented, leading to the 
generation of MHC-class I restricted immunity.  Cross-presentation might 
involve the fusion of phagosome with elements of the ER as one of the 
mechanisms for accessing the MHC class I-processing pathway [232]. Secreted 
antigens, on the other hand, are directly taken up, processed and presented to 
APC/DC, leading to the induction of MHC-class I/II immunity.  This is supported 
by the fact that bone marrow derived DC were capable of TAP-dependent 
presentation of soluble antigen which occurs after macropinocytosis by 




In our study, IHC staining showed that CD11c+/CD8α- DC are the major DC 
subtype infiltrating the immunization site. Despite the large body of evidence 
supporting the existence of multiple DC subtypes, little is known about the 
functions of these DC subtypes in eliciting specific immune response. Different 
DC subtypes are located at various anatomical compartments to exert specific 
immune response.  In spleen, there are two main DC subtypes, CD11c+/CD8α+ 
lymphoid DC and CD11c+/CD8α- myeloid DC.  Similarly, administration of 
human Flt-3L results in expansion of multiple DC subtypes, mainly on 
CD11c+/CD8α+ lymphoid DC and CD11c+/CD8α- myeloid DC.  However, little 
is known on the gene expression profiles, migratory properties and localization 
patterns of these subsets during immune responses.  In terms of function in 
immunity, CD8α+ and CD8α- DC have been associated with T cell polarization.  
Nevertheless, there are no definite reports on functions of these DC subtypes. 
Initial studies by Suss et al [234] demonstrated that splenic CD8α- DC induced a 
vigorous CD4+ T cell proliferative response whereas CD8α+ DC induced a lesser 
response that was associated with T cell apoptosis.  This programmed cell death 
was shown to be due to interaction of Fas on T cells with FasL on CD8α+ DC.  
These findings led to the appealing hypothesis that FasL+ CD8α+ DC could be 
involved in the tolerance of peripheral T lymphocytes, whereas the CD8α– DC 
would induce immunity.   
 
Other than the differences in the ability to polarize T cell immunity, both DC 
subsets exhibit different homing properties.  In our study, CD11c+/CD8α- were 
recruited to the intramuscular immunization site.  This notion was consistent with 
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the poor migratory properties of CD11c+/CD8α+ DC.  It has been shown that 
donor CD8α- DC when given to recipient mouse subcutaneously could be found 
later in DLN.  However, CD8α+ DC were absence in the DLN [23].  The 
identification of CD11c+/CD8α- DC within the mononuclear cell infiltrates 
suggesting that this DC subtype is involved in the induction of muc-1 specific 
immune response.  However, we can not rule out the possibility of other APC 
such as macrophages in eliciting the specific immune response.   
 
As we demonstrated that DC recruitment to immunization site is crucial, we 
postulated that systemic expansion of DC prior to DNA immunization would 
enhance the immune response.  However immunization with pNGVL3-hFLex-
muc-1 with or without initial DC expansion by pNGVL3-hFLex generated a 
comparable immune response.  The underlying reasons are unknown. Ludwig et 
al [235] reported that by using a combination of experimental mouse studies, 
mathematical modeling, and nonlinear parameter estimation, it is found that the 
induction of high avidity CTL, the number of DC was of minor importance once 
a minimal threshold of DC had been reached. The threshold of DC in eliciting 
potent T cell immunity varies with immunization strategy.  Further investigation 
is required to elucidate the underlying mechanism.   
 
The main function of the hFlt-3L component was to expand and recruit DC.  We 
have shown that this function is critical for the efficacy of the DNA vaccine as 
inoculation with pNGVL3-muc-1 DNA vaccine intramuscularly failed to produce 
significant immune response.  Likewise, GM-CSF, a growth factor required to 
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derive bone marrow DC in vitro, has been shown to improve the effectiveness of 
DNA vaccines when co-expressed with antigen on the same plasmid, resulting in 
augmented antigen-specific tumor immunity [236]. Therefore the co-expression 
of human Flt-3L and muc-1 epitope on the same plasmid could provide a novel 
treatment for muc-1-expressing tumor.  In our system, Flt-3L acts to enhance 
immunity against muc-1 antigen, possibly by increasing DC recruitment to the 
immunization sites where antigen is produced.  This suggests that in situ DC 
expansion or recruitment provide a basis for improving DC-based 
immunotherapy.  This is supported by a pilot study on human subjects where 
systemic expansion of DC did not enhance peptide vaccine administered 
intradermally [237].   The failure to induce potent T cell immunity was postulated 
due to the absence of DC recruitment to the immunization sites.   
 
Collectively, our results suggest that co-expression of antigen and human Flt-3L 
in the same plasmid is a promising strategy to elicit a protective Th1 response of 
a sufficient magnitude to generate resistance against tumors. The efficacy of the 
DNA vaccine is also dependent on the routes of immunization.  Furthermore, it is 
in situ, not systemic, expansion or recruitment of DC that enhances the efficacy 
of a DNA vaccine delivered intramuscularly. 
 
4.2.1  Routes of DNA immunization 
One feature of genetic immunization that has become apparent over the past few 
years is that the way a DNA vaccine is delivered may have an effect on the type 
of immune response generated.  In our study, unlike intramuscular immunization, 
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hydrodynamic-based intravenous delivery of DNA vaccine failed to provide anti-
tumor response. The mechanism(s) by which immunization routes affecting the 
type of immune response generated remains unclear.  Successful DNA 
immunization has been demonstrated via various routes of gene delivery 
including intravenous, intramuscular, intraepidermal, intranasal, intraviginal, 
intrasplenic and intrahepatic.  Recently, a novel intravenous gene delivery system 
via hydrodynamic-based tail vein injection has not been investigated as an 
immunization route in murine model.  In fact, this delivery system is not feasible 
in human subjects due to its large volume and high speed of injection. 
Nevertheless, this gene delivery method is efficient in inducing gene expression 
of naked plasmid DNA as compared to conventional intravenous gene delivery 
system.   
 
How the route of DNA immunization affecting the quality of immune response 
does remains to be determined.  It is becoming evident that method and route of a 
DNA vaccine administered can affect the T helper cell profile generated. Upon 
activation, CD4+ T helper lymphocytes differentiate from precursor Th0 cells into 
two functionally distinct subsets. Type 1 (Th1) cells induce cell-mediated 
immunity, including CTL responses, whereas type 2 (Th2) cells primarily induce 
humoral immunity. Intramuscular needle injection of DNA produces a 
predominantly Th1-type response, with an elevated IgG2a:IgG1 ratio and IFN-γ 
production [220,238], characteristics of Th1 response.  In contrast, epidermal 
gene gun inoculation generally induces a Th2 phenotype [239-240].   Intradermal 
injections of DNA have been reported to induce both Th1 [237-239] and Th2 
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[235] profiles, while intramuscular gene gun inoculation seems to generate a 
profile similar to epidermal gene gun inoculation.  It had been reported that 
tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when 
administered by intramuscular needle injection but not by epidermal gene gun 
bombardment [241].  The reasons why different T helper subsets arise after 
different immunization methods are not clear.  One possibility is that it may be a 
dosage phenomenon and the local microenvironments of the immunization site 
i.e. the constituents of various immune cells. 
 
One might ask whether the inherent bias of a particular immunization method can 
be overcome in order to have a greater manipulation of vaccines.  The primary 
immunization mode in some cases appears to irreversibly determine the profile 
produced.  However, the cytokine profile can be shifted by coadministration of 
genes encoding various cytokines or CpG motif-containing oligonucleotides.  
Zhou and colleagues [240] demonstrated that codelivery of unmethylated CpG 
motif containing oligonucleotides with recombinant plasmid DNA encoding for 
hepatitis B surface antigen by gene-gun immunization can shift immune response 
from Th2 to Th1 response. 
 
4.2.2  CpG motif 
One aspect of DNA immunization that has recently drawn significant attention is 
the immunostimulatory properties of DNA itself.  The immunogenicity of DNA 
vaccines is partially attributable to the adjuvant properties of bacterial plasmid 
DNA.  It is well documented that DNA from bacteria can induce non-specific 
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immune response [242]. Bacterial DNA can stimulate NK cell activity and 
cellular immunity through the induction of inflammatory cytokines such as IFN-γ 
and IL-12 [242]. The efficacy of genetic vaccine can be enhanced if a DNA 
vaccine whose plasmid DNA backbone contained CpG motif.  CpG motif 
consists of unmethylated CpG dinucleotides flanked by two 5’ purines and two 3’ 
pyrimidines.  Sato and colleagues [243] showed that CpG-motif-containing-DNA 
vaccine generating a more vigorous antibody and CTL response as compared to 
control vaccine. This demonstrates that the plasmid vector itself could have a 
significant adjuvant effect on DNA vaccine-induced immunity. CpG motif 
generally, induce Th1-like pattern of cytokine production, accounted for strong 
CTL response. More studies confirmed that CpG motifs can enhance genetic 
vaccine potency.  The Th1-promoting ability of plasmid DNA was further 
demonstrated by two recent studies in which mice were injected intradermally or 
intramuscularly with both plasmid DNA and a protein antigen. While protein 
vaccination typically induces a predominantly Th2 response, in both studies co-
immunization with CpG-containing DNA shifted the immune response back 
toward a Th1 or Th0 response, with elevated IgG2a and IFN-γ production [244-
245]. This Th1-inducing activity of bacterial DNA may be a reason why most 
DNA vaccines studied to date induce a predominantly Th1 response when 
injected intramuscularly or intradermally.  Recently, it has been shown that CpG 





4.2.3  Immunization regimen 
In peptide or DNA immunization, the optimal regimen for administering a cancer 
vaccine is far from determined.  The optimal regimen refers to dosage, number 
and/or frequency of a vaccine to be delivered.  It is often thought that multiple 
immunizations will likely be necessary to maximize immune responses, but 
questions of ‘how many’ and ‘how often’ have yet to be answered.  It is 
becoming evident that immunization regimen will affect the nature of the 
resulting immune response. Gene gun immunization of mice with an HIV-1 env 
DNA vaccine for 1x, 2x and 3x generated strong CTL and weak antibody 
responses [246].  However, a fourth immunization caused a drop in CTL activity 
and a marked rise in antibody titers.  The other unknown parameter affecting the 
resulting immune response is the timing of successive immunization with a DNA 
vaccine.  In general, most immunizations adopt ‘prime-and-boost’ strategy.  It 
has been demonstrated that longer rest period between immunizations could 
enhance the resulting immune response [247].  To date, there isn’t any definite 
answer to these differences.  Walh et al [248] demonstrated that protective 
antibody levels against hepatitis B virus can be achieved more rapidly in humans 
through vaccination with short intervals (0, 2 and 6 weeks).  The recommended 
schedule for pre-exposure HB prophylaxis is 0, 1, and 6 months.  
 
4.3  DC-based peptide vaccine and DNA vaccine  
Peptide vaccine and DNA vaccine represent two distinct types of cancer vaccines.  
For peptide immunization strategy, prior knowledge of antigenic epitopes of a 
potential tumor antigen has to be first identified.  Usually, this offers a limited 
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number of epitopes. In addition, most of the antigenic peptides are MHC-
restricted, therefore prior knowledge of host haplotypes has to be sought. In 
contrast to peptide-based immunization approaches, DNA immunization allows 
the involvement of multiple different antigenic epitopes and a broad range of 
MHC restriction. Thus, DNA vaccination, in contrast to peptide immunization, 
does not require prior knowledge of host haplotypes.  DNA immunization 
generates a more long-lasting immunity. This may attributable to the long-term 
expression of the encoded proteins by the host’s cells.  Gene expression in the 
skeletal muscle can be detected for up to 19 months after injection [249].  The 
high susceptibility of peptides to protease is considered to be a drawback for their 
use in immunotherapy. Stemmer et al [250] demonstrated the stability of GP33 
peptide by collecting mouse sera following intravenous delivery of 200μg peptide 
at various time points and tested for its ability to stimulate proliferation. It was 
found that the mouse sera collected at 60 min induced only 30% of proliferative 
response as compared to sera collected at 5 min post-intravenous injection of 
GP33 peptide. This showed that the stability of peptide is short-lived. In addition, 
DNA vaccines offer a number of practical advantages.  First, plasmid DNA can 
be easily and cheaply produced in large quantities. They can be easily 
manufactured into pharmaceutical product as they do not require special handling 
or storage conditions.  In contrast, synthetic peptide is more expensive and the 
purity of synthetic peptide may subject to batch-to-batch variations. Secondly, 
DNA vaccine is feasible to manipulation.  Immunostimulatory sequences 
encoded for CpG motifs or cytokines can be easily incorporated into plasmid 
DNA backbone.  Nevertheless, peptide vaccines have its merits too.  Peptide 
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vaccine is relatively safer than DNA vaccine.  Naked plasmid DNA stands a 
chance to incorporate into host genome. 
 
4.4  Prophylactic and therapeutic tumor immunity 
Our results show that DNA immunization with chimeric plasmid DNA encoding 
both Flt-3L and muc-1 antigen could effectively protect immunized host from a 
subsequent tumor challenge. How can this observation be applied in treating 
human malignancies?  It is suggested that after surgical removal of tumors, the 
cancer patients can be vaccinated with the chimeric DNA vaccine. Tumor 
recurrence remains as one of the setbacks in cancer treatment.  It is hoped that by 
using appropriate vaccination strategy, a long-lived tumor immunity can be 
elicited, thereby reducing the chances of tumor recurrence.  However, we have 
not investigated the therapeutic potential of the chimeric DNA vaccine against 
pre-established, rapidly growing tumors. Tumor-associated antigens are generally 
weak antigens which require appropriate immunization strategies to boost 
immune responses against these antigens. 
 
 
4.5  Conclusion 
Our data suggest that the availability of DC at the antigen site (in situ) is crucial 
to enhance the immunogenicity of peptide and DNA vaccine, providing the basis 
for human trials.  Most importantly, we devised two immunization strategies of 
inducing DC to prime muc-1 specific anti-tumor response in vivo.  Undoubtedly, 
additional studies are needed to improve the strategy and eventually optimize the 
approach for clinical settings, allowing alternative cellular immunotherapy for 
cancer. 
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 4.6  Future studies 
The ability of tumors to escape immune surveillance suggests that the immune 
mechanism is often insufficient to suppress the outgrowth of tumors. In an 
attempt to bolster anti-tumor immunity, this study focuses on a strategy to 
enhance the ability of the adaptive immune system to recognize the tumor cells as 
foreign by expanding/recruitment DC in situ. This strategy may eventually 
obviate the need for ex-vivo manipulation of DC. Although the vaccination 
approaches described above have demonstrated protective activity and feasibility, 
the therapeutic potential of the chimeric DNA vaccine against pre-established 
tumors have yet to be proven. This is a challenging aspect of tumor 
immunotherapy. Active immunity to tumors is usually ineffective when host’s 
tumor burden is excessive. In addition, immunosuppressive of tumor 
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